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This article summarizes the presentations given at an ESPEN Workshop on “Lipids in the ICU” held in Tel
Aviv, Israel in November 2014 and subsequent discussions and updates. Lipids are an important
component of enteral and parenteral nutrition support and provide essential fatty acids, a concentrated
source of calories and building blocks for cell membranes. Whilst linoleic acid-rich vegetable oil-based
enteral and parenteral nutrition is still widely used, newer lipid components such as medium-chain
triglycerides and olive oil are safe and well tolerated. Fish oil (FO)-enriched enteral and parenteral
nutrition appears to be well tolerated and confers additional clinical benefits, particularly in surgical
patients, due to its anti-inflammatory and immune-modulating effects. Whilst the evidence base is not
conclusive, there appears to be a potential for FO-enriched nutrition, particularly administered peri-
operatively, to reduce the rate of complications and intensive care unit (ICU) and hospital stay in sur-
gical ICU patients. The evidence for FO-enriched nutrition in non-surgical ICU patients is less clear
regarding its clinical benefits and additional, well-designed large-scale clinical trials need to be con-
ducted in this area. The ESPEN Expert Group supports the use of olive oil and FO in nutrition support in
surgical and non-surgical ICU patients but considers that further research is required to provide a more
robust evidence base.
© 2017 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.U” held in Tel Aviv, Israel on
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Patients in an intensive care unit (ICU) are heterogeneous and
include surgical and medical patients, mechanically-ventilated or
non-ventilated, obese or undernourished, preterm infants to older
adults, requiring either short-term or long-term intensive care [1].
Nutrition support is critical in maintaining homeostasis in the ICUism. All rights reserved.
care unit: Recommendations from the ESPEN Expert Group, Clinical
P.C. Calder et al. / Clinical Nutrition xxx (2017) 1e182patient and to provide nutrients for the maintenance of lean body
mass as well as repair and maintenance of organ function and
support of defense and healing processes.
Enteral nutrition (EN) comprises specialized liquid nutrition
delivered through a nasogastric or post-pyloric feeding tube into
the stomach or small intestine (duodenum/jejunum), respectively
[2]. The European Society for Clinical Nutrition and Metabolism
(ESPEN) guidelines recommend that EN should be given to all ICU
patients who are not expected to be taking a full oral diet within
three days [3].
Whilst ESPEN acknowledges that there are no definitive data
supporting the early use of EN in terms of clinical outcomes, its
guidelines recommend that hemodynamically stable critically ill
patients who have a functioning gastrointestinal tract should be
fed early (<24 h) using an appropriate amount of feed [3]. Early
initiation of EN is also recommended by the American Society for
Parenteral and Enteral Nutrition (ASPEN) and the Canadian Society
of Critical Care Medicine (SCCM) [4], as well as the European So-
ciety of Intensive Care Medicine (ESICM) [5]. Administration of
early EN in critically ill patients appears to also have a positive
economic impact, with analysis suggesting that it is associated
with significantly reduced costs relating to reduction in ICU stay
and duration of mechanical ventilation compared with standard
care [6].
There are a number of nutritional and non-nutritional benefits
associated with early EN feeding. These include the maintenance of
lean body mass, gut integrity, mucosal associated lymphoid tissue
and muscle function, together with attenuation of oxidative stress
[7]. Studies performed after the publishing of ESPEN guidelines
have demonstrated positive clinical outcomes with early EN
administration, such as reduction in duration of mechanical
ventilation, reduction in length of ICU stay and higher survival rates
in critically ill mechanically-ventilated patients, compared
with delayed EN administration [8,9]. Furthermore, two meta-
analyses investigating early EN (<24 h) in critically ill and trauma
patients reported a significant mortality reduction versus standard
care and a significant reduction in incidence of pneumonia [10,11].
The macronutrient content of several EN formulas used in
clinical practice or in experimental studies is detailed in Table 1; it
is evident that these differ greatly in content of macronutrients and
in individual bioactive nutrients including glutamine, arginine and
omega-3 fatty acids. Hence the metabolic, physiologic and clinical
impact of different EN formulas will differ.
Parenteral nutrition (PN) is nutrition support provided through
intravenous administration of nutrients such as amino acids,
glucose, lipids (as emulsions), electrolytes, vitamins and trace ele-
ments. PN can be provided through a central venous line or through
a peripheral intravenous line [12]. The ESPEN Guidelines forTable 1
Macronutrient composition of EN formulas commonly used in research studies.
Oxepa1 Pulmocare1
Protein (g/l) 63 63
Carbohydrate (g/l) 105 105
Fat (g/l) 93 93
(MCT, canola oil,
fish oil, borage oil)
(MCT, canola oil, corn oil,
high oleic safflower oil)
Omega-6 PUFAs (g/l) 18.4 18.4
Of which GLA (g/l) 4.3 0
Omega-3 PUFAs (g/l) 10 4.8
Of which EPA þ DHA (g/l) 6.5 0
Also contains Taurine, carnitine,
vitamin C, a-tocopherol,
b-carotene
Taurine, carnitine, vitamin C,
a-tocopherol, b-carotene
Source: 1Abbott Nutrition company website; 2Taken from [68]; 3Taken from [202] and N
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who are not expected to be on normal nutrition within 3 days
should receive PNwithin 24e48 h, if EN is contraindicated or if they
cannot tolerate EN [13]. Furthermore, supplementary PN may also
be initiated alongside EN in critically ill patients to help achieve
energy and protein targets.
In terms of the safety of PN compared with EN in critically ill
patients, whilst PN is associated with a lower mortality risk,
particularly when compared to late EN, it has an increased risk of
infectious complications [14,15]. Compared to standard care (oral
diet when tolerated plus iv dextrose) in malnourished patients, EN
appears to be associated with a lower risk of infection, whilst PN
confers a lower risk of mortality as well as infection [16]. Supple-
mental PN may have clinical benefits in addition to reaching
nutritional targets earlier, such as reduced risk of nosocomial in-
fections when initiated on days 4e8 alongside EN compared to EN
alone [17]. However, a recent large scale multi-center randomized
controlled study compared EN to PN and found no significant dif-
ference in mortality and infectious complications [18].
2. Lipids in enteral and parenteral nutrition
Lipids are used in enteral and parenteral nutrition primarily due
to their high caloric content and are thus a good concentrated
source of energy. As such, they lower the amount of carbohydrate
that needs to be provided as part of the nutrition support. Lipids
also provide the building blocks for cell membranes and provide
essential fatty acids, thereby preventing essential fatty acid defi-
ciency. The two essential fatty acids are the omega-6 (n-6) poly-
unsaturated fatty acid (PUFA) linoleic acid (LA) and the omega-3 (n-
3) PUFA a-linolenic acid (ALA). In the body these may be converted
to longer chain, more unsaturated derivatives that have important
biological functions [19]. LA is the metabolic precursor of arach-
idonic acid (ARA) while ALA is the metabolic precursor of eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid (DHA). The
absence of lipids in artificial nutrition support regimens can result
in the onset of essential fatty acid deficiency, especially in preterm
infants, where there is insufficient synthesis of the omega-3 fatty
acid DHA and the omega-6 fatty acid ARA from their essential
precursors [20]. Lipids also allow for delivery of fat soluble
vitamins.
Lipids used in nutrition support contain fats primarily in the
form of triglycerides, with either medium-chain fatty acids (cap-
rylic, capric, lauric and myristic acids), long-chain fatty acids (pal-
mitic, oleic, linoleic and a-linolenic acids) or very long chain fatty
acids (EPA and DHA) [19]. Table 2 details the nomenclature and
sources of fatty acids commonly used as a component of nutrition
support. Triglycerides rich in medium-chain fatty acids have beenEnsure Plus HN2 Impact3 Reconvan4
63 56 55
204 132 120
49 28 33
(MCT, canola
oil, corn oil)
(Palm kernel oil, high oleic
sunflower oil, high oleic
safflower oil, fish oil)
(MCT, safflower oil,
flaxseed oil, fish oil)
7.7 5.8 6.9
0 0 0
1.5 3.3 3.4
0 1.7 2.5
Vitamin C,
a-tocopherol
Arginine, nucleotides, vitamin C,
a-tocopherol, b-carotene
Arginine, glutamine,
vitamin C, a-tocopherol,
b-carotene
estle Health Science company website; 4Fresenius Kabi company website.
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Table 2
Fatty acids of importance in parenteral nutrition.
Fatty acid Shorthand
nomenclature
Oil source
Caprylic acid 8:0 Coconut oil or palm kernel oil
Capric acid 10:0 Coconut oil or palm kernel oil
Lauric acid 12:0 Coconut oil or palm kernel oil
Myristic acid 14:0
Palmitic acid 16:0
Oleic acid 18:1n-9 Olive oil
Linoleic acid 18:2n-6 Vegetable seed oils e.g. soybean oil
a-Linolenic acid 18:3n-3 Vegetable seed oils e.g. soybean oil
Eicosapentaenoic acid 20:5n-3 Fish oil
Docosahexaenoic acid 22:6n-3 Fish oil
P.C. Calder et al. / Clinical Nutrition xxx (2017) 1e18 3termed medium-chain triglycerides or MCTs. Soybean oil (SO)
which is rich in linoleic acid, has been termed long-chain tri-
glycerides or LCTs, although strictly speaking any triglyceride
composed of long-chain fatty acids is a LCT. Fatty acid chain length,
and the presence, number and position of double bonds affect
physical, physiological and functional properties of the fatty acid
[19]. Hence, different fatty acids can influence, in different ways, a
number of different physiological processes such as metabolism,
inflammation, immune response, oxidative stress, blood coagula-
tion, organ function and wound healing [19].
The blend of lipids used in nutrition support has evolved over
time. This is well illustrated by considering the lipid emulsions
(LEs) used in PN (Fig. 1). The first generation of such LEs consisted
purely of SO, with the second generation LEs including MCTs and
the third generation beginning with the inclusion of structured
lipids and olive oil (OO). Most recently third generation LEs con-
taining fish oil (FO) have been introduced. Current commercially
available LEs used in PN are detailed in Table 3 and include: pure
SO; a 50:50 mixture of SO and MCTs (SO/MCT); inter-esterified SO
and MCTs; a 20:80 mixture of soybean and olive oils (SO/OO; this is
referred to herein as olive oil-based); a 40:50:10 mixture of SO,
MCTs and FO (SO/MCT/FO); a 30:30:25:15 mixture of SO, MCTs,
olive oil and FO (SO/MCT/OO/FO); and pure FO [21]. Additional
components of lipid PN formulations include varying amounts of
phytosterols (cholesterol-like structures that are present in plant
oils); a-tocopherol and other fat-soluble bioactives, depending on
the fat source; and phospholipids, usually phosphatidylcholine
(sometimes called lecithin), as an emulsifier.
The major physiological effects of the key fatty acids found in
different lipids are summarized elsewhere [19,22,23]. SO is a source
of the essential omega-6 PUFA LA, which comprises about 50% of
the fatty acids present and is the metabolic precursor of ARA. SO
also contains some (~7% of fatty acids) of the essential omega-3
PUFA ALA. Because it is a precursor of ARA, an excess of LA is
considered to promote inflammation, immunosuppression,Fig. 1. Evolution of lipid emulsions for use in parenteral nutrition.
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Nutrition (2017), http://dx.doi.org/10.1016/j.clnu.2017.08.032coagulation, and fatty liver (hepatic steatosis) [24], although
conclusive evidence for this is lacking. However, it is clear that high
amounts of LA do impair synthesis of the omega-3 PUFAs EPA and
DHA [25].
MCTs, a source of medium-chain saturated fatty acids usually
from coconut oil, are a good energy source whilst not affecting
blood triglyceride levels. They are ketogenic and protein sparing,
and are relatively resistant to peroxidation [26,27]. MCTs do not
appear to impair liver, immune or lung function [26,27]. However,
rapid infusion of such a lipid emulsion in patients suffering from
acute respiratory distress syndrome resulted in a deterioration of
lung function and hemodynamics [28].
OO, a source of oleic acid, is relatively neutral in its physiological
effects, for example on immune function, inflammation and blood
coagulation [29]. Because of its high content of monounsaturated
fatty acids, OO ismore resistant to peroxidation and oxidative stress
than SO. Importantly, OO also preserves hepatobiliary function [30].
FO, a good source of EPA and DHA, is anti-inflammatory andmay
promote immune function and improve hepatic metabolism and
liver function, including reversal of intestinal failure-induced fatty
liver and cholestasis [19,23,31]. EPA and DHA also have anti-
coagulation and anti-arrhythmic effects, and oppose the actions
of omega-6 PUFAs [19,23]. However, being very long chain, highly
unsaturated fatty acids, both EPA and DHA are prone to
peroxidation.
Lipids provided in EN are subject to the normal intestinal pro-
cesses of digestion and absorption, with the products appearing in
the bloodstream as triglyceride components of chylomicrons. LEs in
PN bypass intestinal processes and so may be metabolized differ-
ently from lipoproteins originating from the gut. Once infused, the
LEs, comprising triglycerides stabilized with a shell of phospho-
lipids, acquire endogenous apoproteins that enable binding to and
activation of lipoprotein lipase [32]. The structure of LEs (i.e., their
fatty acid composition) appears to affect their rate of plasma
clearance and hence tissue uptake. Animal studies have demon-
strated that synthetic triglycerides comprising two medium chain
and one long chain fatty acid clear faster than either MCTs or LCTs
alone [33,34], an effect which is also observed in humans [35]. The
addition of FO to an SO/MCT emulsion (SO:MCT:FO 40:50:10)
resulted in faster plasma clearance than SO/MCT in both mice and
humans [36,37].
The hydrolysis of circulating triglycerides arising from either
enteral or parenteral lipid, yields free fatty acids that may enter
adjacent tissues or remain in the circulation. The essential omega-3
PUFA ALA is not well incorporated into membrane phospholipids.
However, the essential omega-6 PUFA LA, its metabolite ARA, and
the metabolites of ALA EPA and DHA are incorporated into cell
membrane phospholipids and into membrane lipid raft regions,
thereby affecting the structure and function of membrane-bound
proteins [19,21]. Thus these different PUFAs play a key role in cell
membrane structure and function, regulation of gene expression
and cell signaling pathways involved in apoptosis, metabolism,
inflammation, cell-mediated immunity, blood clotting and organ
function as well as synthesis of bioactive lipid mediators such as
eicosanoids and docosanoids [19,21,22]. Eicosanoids are signaling
molecules synthesized from 20-carbon PUFAs and include the
prostaglandins (PGs), thromoboxanes (TXs) and leukotrienes (LTs)
produced from ARA and EPA. Lipoxins produced from ARA and
resolvins produced from EPA are also eicosanoids. Docosanoids are
signalingmolecules synthesized from 22-carbon PUFAs and include
the resolvins, protectins and maresins produced from DHA.
Once incorporated into cell membranes, the metabolism of
omega-6 and omega-3 PUFAs results in the production of eicosa-
noids and docosanoids that have differing roles in inflammation
and immune response, platelet aggregation smooth-musclecare unit: Recommendations from the ESPEN Expert Group, Clinical
Table 3
Oil and typical fatty acid compositions (% of total) of commercially available lipid emulsions for use in parenteral nutrition.
Intralipid® Lipofundin®
MCT/LCT
Structolipid® Omegaven® ClinOleic® Lipoplus®
(also known as Lipidem®)
SMOFlipid®
Oil source 100%
soybean
50% MCT þ 50%
soybean
36% MCT þ 64%
soybean
100% fishc 80% olive þ 20%
soybean
50% MCT þ 40%
soybean þ 10% fishc
30% MCT þ 30%
soybean þ 25%
olive þ 15% fishc
SFA 15 58 46 21 14 49 37
MUFAa 24 11 14 23 64 14 33
PUFA 61 31 40 56 22 37 30
n-3 PUFA 8 4 5 48 3 10 7
ALA 8 4 5 1 3 4 2
EPA e e e 20 e 3.5 3
DHA e e e 19 e 2.5 2
n-6 PUFAb 53 27 35 5 19 27 23
Information taken from [203e205].
SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.
a Mainly oleic acid.
b Mainly linoleic acid.
c The fatty acid composition of fish oil is more variable than that of vegetable oils so that the precise contribution of different fatty acids may differ in different batches.
Note that the fish oil used in Lipolus® is more concentrated in EPA and DHA than that used in SMOFLipid® so that 10% fish oil in Lipoplus® provides more EPA and DHA than
15% fish oil in SMOFLipid®.
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to pro-inflammatory lipid mediators such as the 2-series PGs and
TXs and the 4-series LTs [38,39]. It also gives rise to anti-
inflammatory and inflammation resolving lipoxins [40]. Preclini-
cal studies have highlighted the importance of lipid mediators
produced from ARA in sepsis. Direct inhibition of cyclooxygenase-2
and 5-lipoxygenase, enzymes involved in the synthesis of ARA-
derived pro-inflammatory mediators (PGs, TXs, LTs), results in
increased lipoxins which attenuate the inflammatory response and
protect from sepsis [41]. Furthermore, administration of ARA-
derived lipoxin A4 in a mouse model of sepsis increased survival
through reduction of systemic inflammation and blood bacterial
load [42]. The omega-3 PUFAs EPA and DHA compete with ARA and
result in synthesis of weaker pro-inflammatory 3-series PGs and
TXs and 5-series LTs [43]. EPA and DHA also give rise to resolvins
(both EPA and DHA), protectins and maresins (DHA only), which
play a key role in resolution of inflammation, reduction of tissue
injury and promotion of wound healing [44]. Resolvins reduce the
inflammatory response via decreasing neutrophil invasion, reduc-
tion of synthesis of pro-inflammatory cytokines via inhibition of
NF-kB, recruitment of monocytes, increased phagocytosis of
apoptotic neutrophils and facilitation of removal of macrophages
via the lymphatic system [44,45]. Rodent models have demon-
strated that the inflammation-resolving effect of DHA-derived
resolvin D2 is associated with increased survival in bacterial
sepsis [46]. Resolvin D2 was able to decrease local and systemic
bacterial burden, excessive cytokine production and neutrophil
recruitment, whilst increasing macrophage phagocytosis [46]. EPA
and DHA also exert an anti-inflammatory effect acting through
other mechanistic pathways, including suppression of nuclear
factor kappa B signaling via activation of the cell surface GPR120
protein and the intracellular receptor peroxisome proliferator
activated receptor g, and thus inhibition of production of a range of
pro-inflammatory cytokines, adhesion molecules, cyclooxygenase-
2, inducible nitric oxide synthase and matrix metalloproteinases
[19,43].
It is evident from the forgoing discussion that individual fatty
acids have unique functional properties and that different members
of the same fatty acid family (saturated, omega-6, omega-3) do not
share the same properties [19]. For this reason, it is important that
discussion of the role of the fatty acid composition of lipids to be
used in nutritional support of patients in the ICU (or elsewhere)
should focus on individual fatty acids rather than on fatty acidPlease cite this article in press as: Calder PC, et al., Lipids in the intensive
Nutrition (2017), http://dx.doi.org/10.1016/j.clnu.2017.08.032families. Therefore, discussion of compositional properties such as
the omega-6 to omega-3 ratio is not valuable. This is because this
ratio can be altered in many different ways that may not have the
same functional or clinical impact. For example, the omega-3 fatty
acid component may be altered by using more ALA or by using
more EPA þ DHA and the outcome from those two scenarios is
likely to be different. This is discussed further elsewhere [47,48].
3. Fish oil-enriched EN in critically ill patients
ESPEN guidelines state that an immune-modulating EN formula
enriched with arginine, nucleotides and omega-3 fatty acids is
superior to standard enteral formula in certain groups of patients,
i.e. upper gastrointestinal surgical patients, trauma patients and
patients with mild sepsis [3]. No benefit has been established in
patients with severe sepsis, in whom an immune-modulating for-
mula may be harmful and is therefore not recommended [3].
ASPEN and SCCM have previously issued similar guidelines [4], but
these have been modified recently and suggest that immune-
modulating enteral formulations (containing arginine with other
agents, including omega-3 fatty acids, glutamine and nucleic acids)
should not be used routinely in the medical ICU [49]. Consideration
for these formulations should be reserved for patients with trau-
matic brain injury and perioperative patients in the surgical ICU
[49].
Regarding critically ill patients with acute respiratory distress
syndrome (ARDS) and severe acute lung injury (ALI), ESPEN
guidelines state that such patients should receive an enteral
formulation characterized by an anti-inflammatory lipid profile (i.e.
omega-3 rich FO, borage oil) and antioxidants [3], a guideline
previously supported by ASPEN and SCCM [4]. However, in 2013,
the Canadian Clinical Practice Guidelines reviewed new study data
investigating the effect of such EN formulas in critically ill patients
with ALI/ARDS and downgraded the recommendation to “should be
considered” from “recommended” due to a diminished effect on
mortality risk [50]. Furthermore, ASPEN in 2016 decided not to
make any recommendation in this area [49]. Details of the studies
discussed in the following sections may be found in Table 4.
3.1. ALI/ARDS
ARDS is characterized by diffuse pulmonary inflammation,
increased vascular permeability and edema [51,52]. Whilst acare unit: Recommendations from the ESPEN Expert Group, Clinical
Table 4
Clinically relevant outcomes of studies using fish oil-enriched EN in critically ill patients.
Study Population
(Number
enrolled/included
in analysis)
Intervention EPA
(g/d)
DHA
(g/d)
GLA
(g/d)
Control Outcome in intervention group
Braga et al. 2002 [69] Major abdominal
surgery for GI
malignancy
(196/150)
Peri- & post-operative
IMPACT®
~2.9 EPA þ DHA 0 Post-operative
standard EN
Y Number of complications
Y Hospital length of stay
Elamin et al. 2012 [59] ARDS
(22/17)
Oxepa® N/A N/A N/A Pulmocare® [ Oxygenation
Y Lung injury
Y Organ dysfunction
Y ICU stay
Gadek et al. 1999 [56] ARDS
(146/98)
Oxepa® 6.9 2.9 5.8 Pulmocare® [ Oxygenation
Y Ventilator days
Y New organ failure
Y ICU stay
Grau-Carmona et al. 2011 [60] Septic patients
with ALI/ARDS
(160/132)
Oxepa® 5.4 2.3 4.9 Ensure Plus HN® [ Oxygenation
Y New organ failure
Y ICU stay
Kagan et al. 2015 [71] Severe trauma
(120/99)
Oxepa® 5.5 2.3 4.7 Pulmocare® No effect on oxygenation,
incidence of ARDS/ALI, length
of ventilation time, length of ICU
stay or 28-day mortality
Klek et al. 2011 [70] Major abdominal
surgery for GI
malignancy
(341/305)
Post-operative
Reconvan®
~5 EPA þ DHA 0 Post-operative
Peptisorb®
Y Hospital stay
Y Infectious complications
Y Overall morbidity
Y Overall mortality
Pontes-Arruda et al. 2006 [58] ARDS secondary
to sepsis/septic shock
(165/103)
Oxepa® 4.9 2.2 4.6 Pulmocare® [ Oxygenation
Y New organ failure
Y Ventilator days
Y ICU stay
Y Mortality
Pontes-Arruda et al. 2011 [68] Early stage
sepsis
(115/106)
Oxepa® 4.6 2.0 4.4 Ensure Plus HN® Y Progression of sepsis
Y Respiratory and cardiac failure
Y ICU stay
Rice et al. 2011 [61] ARDS/ALI
(272/272)
Bolus FO þ GLA 6.8 3.4 5.9 Equivalent with
no FO or GLA
No clinical benefit. Trial stopped
early due to fewer ventilator-free
and ICU-free days, and greater
60-day mortality in FO group
Singer et al. 2006 [57] ALI
(100/95)
Oxepa® 5.4 2.5 5.1 Pulmocare® [ Oxygenation
Y Ventilator duration
Stapleton et al. 2011 [62] ALI
(90/85)
Bolus FO 9.8 6.8 0 Equivalent with
no FO
No effect on SOFA, ventilator
free days or mortality
Van Zanten et al. 2014 [73] Medical/surgical/
trauma ICU patients
(301/301)
Experimental high
protein feed enriched
with glutamine,
omega-3 fatty acids &
antioxidants
~4.5 EPA þ DHA 0 Protison
(high protein
feed)
No effect on infections, mortality,
organ failure, duration of mechanical
ventilation or length of stay.
Increased 6-month mortality rate
reported in medical sub-group.
SOFA, Sequential Organ Failure Assessment score.
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(old definition [53]) and the term is still used in preclinical models,
ALI is now defined as mild ARDS (Berlin Definition). Evidence from
preclinical models of ALI/ARDS suggests that nutritional supple-
mentation of EN with omega-3 fatty acids may improve vascular
leakage, pulmonary inflammation and gas exchange and oxygen-
ation [54,55].
Several clinical studies in patients with ALI/ARDS have shown
that continuously-administered EN enriched with EPA, DHA, g-
linolenic acid (GLA, an omega-6 fatty acid present in borage oil) and
anti-oxidants, resulted in improved oxygenation [56e59] and
reduced duration of ventilation [56e58], decreased new organ
failure [56,58,59] and shortened ICU stay [56,58e60] compared
with standard EN. There is little evidence supporting the use of this
formulation in mortality reduction in this patient population, apart
from one study in patients with ARDS secondary to sepsis [58].
In contrast to these positive findings, two studies that utilized
bolus administration of enteral FO in patients with ALI, found no
clinical benefit compared with standard EN [61,62], with one trial
being stopped early due to futility and reporting fewer ventilator-Please cite this article in press as: Calder PC, et al., Lipids in the intensive
Nutrition (2017), http://dx.doi.org/10.1016/j.clnu.2017.08.032and ICU-free days, and a non-significant increase in the 60-day
mortality in the FO group [61]. Compared to continuous adminis-
tration, bolus delivery may not enable sufficient incorporation of
EPA and DHA into cell membranes, which may have played a role in
these negative findings. Furthermore, in one trial, whilst under-
feeding occurred in both intervention and control groups, a five-
fold higher protein intake was reported in the control group,
which is likely also to have contributed to the lack of effect seen in
the study group [61,63].
A meta-analysis of 955 patients with ARDS/ALI concluded that
FO-enriched EN had no effect on 28-day mortality [64]. However, a
sensitivity analysis demonstrated that, on exclusion of the two
studies delivering a bolus of FO, there is evidence that supports the
use of continuous administration of EN containing FO in decreasing
mortality in critically ill patients, including patients with ALI/ARDS
[65]. However, ASPEN decided to make no recommendation at this
time regarding the routine use of an enteral formulation charac-
terized by an anti-inflammatory lipid profile (i.e. omega-3 rich FO,
borage oil and antioxidants) in patients with ARDS and severe ALI,
given the conflicting data [49].care unit: Recommendations from the ESPEN Expert Group, Clinical
P.C. Calder et al. / Clinical Nutrition xxx (2017) 1e1863.2. Sepsis
Sepsis is associated with a hyper-inflammatory response which
directly and indirectly causes widespread tissue damage, through
the release of pro-inflammatory mediators, proteases and oxidants
from activated macrophages, as well as vasodilators such as nitric
oxide, which acts as a key mediator in septic shock [66,67].
Whilst no definitive study demonstrates that the use of EN
enriched with omega-3 fatty acids results in improved outcomes
for critically ill patients with sepsis, there does appear to be clinical
benefit when administered in early-stage sepsis. Specifically, in
patients without any sepsis-associated organ failure, administra-
tion of FO-enriched EN resulted in reduction in the progression of
sepsis as well as in respiratory and cardiac failure and a reduced
length of ICU stay compared with a lower lipid-containing EN [68].
3.3. Major abdominal surgery
There is evidence supporting the use of FO-enriched EN inmajor
abdominal surgery. Peri-operative administration of EN containing
arginine, omega-3 fatty acids and RNAwas reported to reduce post-
operative complications and hospital length of stay in malnour-
ished cancer patients undergoing major abdominal surgery versus
standard post-operative EN [69]. Furthermore, immune-
modulating EN (containing omega-3 fatty acids, arginine and
glutamine) administered post-operatively to malnourished pa-
tients undergoing resection for pancreatic/gastric cancer resulted
in a shorter hospital stay, fewer infectious complications and
reduced morbidity and mortality compared to post-operative
standard oligopeptide EN [70].
3.4. Severe trauma
There are few studies assessing the effect of FO-enriched EN
specifically on trauma patients. One study administered pre-
emptively FO-enriched EN (containing EPA, DHA, GLA and anti-
oxidants) to severe trauma patients to assess its effect on the
development of respiratory complications, but found no difference
in the level of oxygenation (PaO2/FiO2 ratio), incidence of ARDS/ALI,
duration of ventilation, length of ICU stay or 28-day mortality
compared with a high fat/low carbohydrate EN formulation [71].
However, whilst red blood cell EPA, GLA and omega-3 index (the
sum of EPA plus DHA) increased significantly in the study group,
the optimal omega-3 index required for clinical efficacy failed to be
reached, and this may have contributed to the study's negative
findings. This raises the importance of omega-3 fatty acid baseline
measurement in ICU patients, to determine the extent of incorpo-
ration during supplementation; ultimately such measurements
could be used as a predictor of therapeutic efficacy [72].
3.5. Benefit versus harm of immune-modulating EN in ICU patients
The ESPEN guidelines recommend the use of FO-enriched EN in
subgroups of critically ill patients and there are a number of studies
(discussed above) that show clinical benefit of such EN. However, a
recent study has raised questions concerning the benefit and harm
of immune-modulating EN. Van Zanten et al. conducted a multi-
center trial in 301 mechanically ventilated critically ill patients, and
found that high protein EN enriched with immune-modulating
nutrients (glutamine, omega-3 PUFAs, selenium and anti-
oxidants) had no effect on infections and other clinical endpoints
(mortality, organ failure, duration of mechanical ventilation, length
of stay) compared with standard high protein EN [73]. The study
population comprised medical, surgical and trauma ICU patients.
Sub-group analysis found that medical ICU patients had increasedPlease cite this article in press as: Calder PC, et al., Lipids in the intensive
Nutrition (2017), http://dx.doi.org/10.1016/j.clnu.2017.08.0326-month mortality rates in the enriched EN group suggesting that
in this particular medical population, immune modulating EN
should not be used. Specifically, these results, together with the
increased mortality observed in the REDOXS trial [74] raise con-
cerns over the safety of the glutamine component of the enteral
feed in certain ICU patients.
4. Clinical and biochemical effects of different lipid
emulsions in PN used in critically ill patients
ESPEN guidelines recommend that lipids should be an essential
part of PN for energy and to ensure essential fatty acid provision,
and that intravenous LEs can be administered safely at a rate of
0.7 g/kg up to 1.5 g/kg over 12e24 h [13]. However, the choice of
lipid used in PN may have an effect on clinical outcomes in the
critically ill patient.
4.1. Soybean oil-based lipid emulsions
As discussed in Section 2, pure SO may have a number of less
desirable effects on physiological processes, such as promoting
inflammation and suppressing immune function due to its high LA
content, and a tendency for peroxidation due to its relatively low a-
tocopherol content. Pure SO has also been associated with a
number of complications including hyperbilirubinemia and intes-
tinal failure associated liver disease (IFALD). SO intake may increase
the lung flow of lymph and pulmonary pressure, and decrease the
partial pressure of oxygen in arterial blood (PaO2) resulting in
respiratory acidosis, and modify lipid metabolism when compared
to second and third generation lipids [75,76].
There is evidence that SO-based PN might exacerbate the post-
surgical inflammatory response in gastrointestinal surgery patients
with severe surgical-related stress, and impair immune function
when compared to standard glucose-containing PN [77]. The pro-
inflammatory effect of the SO emulsion was not so pronounced in
patients with moderate surgery-related stress. An immunosup-
pressive effect was also seen in polytrauma patients receiving early
SO-containing PN, which was associated with higher rates of
infection, reduced T cell function and lowered natural killer cell
activity [78]. This was linked to longer duration of mechanical
ventilation and longer ICU and hospital stay, compared to standard
glucose-containing PN [78]. However, neither of these studies
examined the impact of other lipids to which the effects of SO could
be compared.
The accumulating evidence base has resulted in a recommen-
dation from the German Society for Nutritional Medicine (DGEM)
that pure SO LEs should no longer be used in PN support of crit-
ically ill patients [79]. DGEM will further refine its recommenda-
tion in its updated guidelines and will advise that ICU patients
should receive second or third generation LEs with reduced con-
tent of omega-6 fatty acids (M. Adolph and K. Mayer, personal
communication; [80]). ASPEN suggest withholding SO-based LEs
during the first week following initiation of PN in the critically ill
patient or limiting this to a maximum of 100 g/wk (often divided
into 2 doses/wk) if there is concern about essential fatty acid
deficiency [49].
4.2. Olive oil-based lipid emulsions
OO-based LEs appear to be a safe alternative to pure SO-based
LEs, which is reflected in the ESPEN guidance that OO-based PN is
well tolerated in critically ill patients [13]. Using OO-based PN in
adult surgical patients results in better fatty acid status, increased
blood vitamin E concentration, decreased lipid peroxidation and
decreased inflammatory variables [81e83]. However, the evidencecare unit: Recommendations from the ESPEN Expert Group, Clinical
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is not consistent. In surgical ICU patients administered OO-based PN
for up to 28 days post-surgery, there was no difference in glycemic
control, immune function, or inflammatory or oxidative stress
markers compared to SO-based PN [84]. Mortality rate, incidence of
nosocomial infections and acute renal failure, as well as length of
stay, were all reported to be similar between the two groups. Mateu-
de Antonio et al. also found no difference in the number or type of
infections, length of ICU or hospital stay or mortality following an
average duration of 19 days of post-operative OO-based PN
compared to SO in surgical ICU patients [85].
4.3. SO/MCT-based lipid emulsions
There is good evidence that supports the use of SO/MCT LEs
instead of pure SO in critically ill patients. A study in severely
malnourished surgical patients receiving peri-operative total PN
reported a significantly lower incidence of intra-abdominal ab-
scesses with SO/MCT versus SO [86]. There was no reported dif-
ference in other infection rates or mortality. SO/MCT is also
associated with a shorter period of mechanical ventilation in crit-
ically ill patients with COPD compared to SO [87].
4.4. Fish oil-containing lipid emulsions
ESPEN guidelines state that addition of EPA and DHA to LEs has
demonstrable effects on cell membranes and inflammatory pro-
cesses, and that FO-enriched lipid emulsions probably decrease
length of stay in critically ill patients [13]. DGEMwill also state that
specific LEs enriched with omega-3 fatty acids may be considered
for administration in critically ill patients (M. Adolph and K. Mayer,
personal communication). There have been a number of studies
investigating the effect of FO-enriched PN in critically ill patients
(see Tables 5e7 for more details about the studies included in the
following sections).
4.4.1. Fish oil-enriched PN in surgical ICU patients
Administration of FO-enriched PN in patients undergoing major
surgical procedures appears to be effective in lowering the post-
operative inflammatory response. For example, suppression of
the pro-inflammatory cytokine IL-6 was reported following
parenteral FO administration in elderly patients undergoing hip
surgery compared to the absence of intravenous FO administration
[88]. Furthermore, perioperative infusion of FO in cardiac surgery
patients significantly increased platelet EPA and DHA and atrial
tissue EPA together with a decrease in IL-6 concentrations, with no
adverse effects reported compared with the saline control [89].
Compared to SO, perioperative FO-enriched PN in surgical ICU pa-
tients decreased post-operative serum IL-6 and whole blood tumor
necrosis factor (TNF)-a production, and increased monocyte
expression of human leukocyte antigen-DR (a marker of immune
competence) [90]. This effect was associated with a shorter hospital
stay in the FO-enriched PN group, but there was no difference in
infection rate or mortality. Administration of FO-enriched PN
(FO þ SO) for 7 d post-gastrointestinal surgery resulted in signifi-
cantly fewer incidences of systemic inflammatory response syn-
drome (SIRS) and significantly shorter hospital stay compared with
SO alone [91]. There was also a trend toward fewer infectious
complications in the FO-enriched PN group. Similar results were
reported for short-term (3 d) pre-operative infusion of FO alone in
gastrointestinal cancer patients awaiting surgery [92]. Adminis-
tration of FO improved the post-operative immune response
(decreased interleukin (IL)-6 and IL-10, decreased leukocyte
oxidative burst, maintenance of monocyte percentage expressing
human leukocyte antigen-DR and CD32, and increased neutrophilPlease cite this article in press as: Calder PC, et al., Lipids in the intensive
Nutrition (2017), http://dx.doi.org/10.1016/j.clnu.2017.08.032CD32 expression) but had no effect on post-operative infections or
length of ICU or hospital stay [92].
There is also evidence supporting the post-operative adminis-
tration of FO-containing PN in gastric surgery patients in improving
post-surgical immune competence, lowering infection rate and
shortening hospital stay. In elderly patients following colorectal
cancer surgery, administration of PN containing FO þ SO for 7 d
resulted in lowered levels of IL-6 and TNF-a and fewer CD8 positive
cells in the bloodstream, fewer infectious complications and in-
cidences of SIRS, and shorter length of hospital stay compared with
SO alone [93]. Furthermore, a study in gastric carcinoma patients
undergoing major abdominal surgery reported that post-operative
PN enriched with FO resulted in fewer infectious complications and
a shorter hospital stay compared with standard PN [94]. A reduced
infection rate was also found in gastrointestinal surgery patients
following 5 days of post-operative PN containing OO/SO enriched
with FO compared to OO/SO alone [95], whilst another study found
a shorter length of hospital stay was associated with FO-enriched
SO/MCT compared to SO alone in gastrointestinal surgery patients
[96]. Decreased length of hospital stay was found to be associated
with 5 days of post-operative administration of SO/MCT/OO/FO-
containing PN compared to SO-based PN in gastrointestinal sur-
gery patients [97]. Furthermore, in liver transplantation patients,
FO-enriched PN given for 7 days post-surgery resulted in a
decreased length of hospital stay compared to SO/MCT [98]. Peri-
operative administration of FO-enriched PN in surgical patients
appears to have a beneficial effect on clinical outcomes as sug-
gested by Heidt et al. from a study in coronary artery bypass graft
patients which resulted in a shortened ICU stay compared to SO-
based PN [99] and Tsekos et al.'s study in gastrointestinal surgery
patients which resulted in decreased mortality, decreased
requirement for mechanical ventilation and decreased hospital stay
compared to SO/MCT-containing PN [100].
These findings are supported by a meta-analysis of 23 studies
including 1502 surgical and ICU patients which investigated the
effects of FO-enriched PN compared with other LEs (SO, SO/MCT,
OO/SO) on various clinical outcomes [101]. Whilst the authors
found no effect on mortality, FO-enriched PN resulted in a clinically
and statistically significant reductions in infection rate and in
length of ICU and hospital stay. A smaller meta-analysis of 7 RCTs
also concluded that post-operative administration of FO-enriched
PN in major abdominal surgery patients has a beneficial effect on
post-operative infection rates and length of ICU and hospital stay
[102]. Furthermore, a meta-analysis of five trials performed by
Manzanares et al. found that FO administered either parenterally or
enterally resulted in a non-statistically significant trend
toward reduced duration of mechanical ventilation [103].
In addition to its positive effects on inflammation and immune
function, FO-enriched PN may help to preserve liver function in
critically ill surgical patients. Decreased total bilirubin as well as
serum IL-6, TNF-a and nuclear factor kappa B was reported in
gastrointestinal surgical patients following post-operative admin-
istration of FO-enriched PN compared with SO/MCT [104]. Rates of
infectious complications and SIRS were comparable between the
two groups. A similar study also utilizing FO-enriched PN versus
SO/MCT in post-operative patients, found similar results, although
statistical significance was not reached for the reductions in liver
dysfunction, infection rate and serum pro-inflammatory cytokines
[105]. In comparison with pure SO, FO/SO (20:80) administered
post-operatively to major abdominal surgery patients resulted in
significantly decreased markers of liver dysfunction (ALT and AST),
bilirubin and lipase [106]. Weight was maintained in the FO-
enriched PN group, as well as a tendency toward shorter ICU stay
in those patients at risk of sepsis [106]. Hence FO-enriched PN
improved liver and pancreas function in this patient population,care unit: Recommendations from the ESPEN Expert Group, Clinical
Table 5
Clinically relevant outcomes from including different lipid emulsions in PN in surgical patients.
Study Population Intervention Duration Control Outcome in intervention group
Badía-Tahull et al. 2010 [95] Gastrointestinal surgery OO/SO þ FO (ClinOleic® þ Omegaven®)
(n ¼ 13)
5 d OO/SO (ClinOleic®) (n ¼ 14) Y Number of infections.
Trend toward lower mortality and fewer
incidences of sepsis.
No effect on length of hospital stay
Berger et al. 2008 [206] Abdominal aorta
aneurysm surgery
SO/MCT/FO (Lipoplus®) (n ¼ 12) 4 d SO/MCT (Lipofundin®)
(n ¼ 12)
Trend toward shorter ICU and hospital stay
Berger et al. 2013 [89] Cardiac surgery FO (Omegaven®) (n ¼ 14) 3 infusions: 12 h and 2 h
before surgery and
immediately after surgery
Saline (n ¼ 14) Trend toward shorter length of mechanical
ventilation and shorter ICU stay
Grimm et al. 2006 [97] Gastrointestinal surgery SO/MCT/OO/FO (SMOFlipid®) (n ¼ 19) 5 d SO (Lipovenoes®) (n ¼ 14) Y Length of hospital stay
Han et al. 2012 [105] Major surgery SO/MCT þ FO (Lipofundin® þ Omegaven®)
(n ¼ 18)
7 d post-surgery SO/MCT (Lipofundin®)
(n ¼ 12)
Trend toward less liver dysfunction and fewer
infections
Heidt et al. 2009 [99] Coronary artery
bypass surgery
FO (Omegaven®) (n ¼ 52) ~12 h prior to surgery
until ward transfer
SO (Lipovenoes®)
(n ¼ 50)
Y Post-operative atrial fibrillation
Y ICU stay
Heller et al. 2004 [106] Gastrointestinal surgery SO þ FO (Lipovenoes® þ Omegaven®)
(n ¼ 24)
5 d post-surgery SO (Lipovenoes®)
(n ¼ 20)
Y Markers of liver dysfunction
Jiang et al. 2010 [91] Gastrointestinal surgery SO þ FO (Intralipid® þ Omegaven®)
(n ¼ 100)
7 d post-surgery SO (Intralipid®) (n ¼ 103) Y SIRS
Y Length of hospital stay
Trend toward fewer infectious complications.
Klek et al. 2005 [94] Gastrointestinal surgery Post-operative FO (Omegaven®)
(n ¼ 30)
Mean duration 9 d SO/MCT (Lipofundin®) (n ¼ 30)
SO/MCT þ glutamine
(Lipofundin® þ Dipeptiven®) (n ¼ 30)
Y Infectious complications
Y Hospital stay
Ma et al. 2012 [108] Gastrointestinal surgery SO/MCT/OO/FO (SMOFlipid®)
(n ¼ 20)
5 d post-surgery SO/MCT (Lipovenoes®)
(n ¼ 20)
No difference in post-operative complications,
infections or duration of hospital stay
Mateu-de Antonio
et al. 2008 [85]
Surgery patients OO/SO (ClinOleic®) (n ¼ 23) Mean duration 19 d SO (Intralipid®) (n ¼ 16) No difference in number and type of infections,
ICU stay, hospital stay or mortality.
Metry et al. 2014 [109] Gastrointestinal surgery SO/MCT/OO/FO (SMOFlipid®) (n ¼ 41) 7 d post-surgery SO (Intralipid®) (n ¼ 42) No difference in ventilation, duration of ICU or
hospital stay or mortality
Piper et al. 2009 [107] Surgery SO/MCT/OO/FO (SMOFlipid®) (n ¼ 22) 5 d post-surgery OO/SO (ClinOleic®) (n ¼ 22) Y Markers of liver dysfunction
de Miranda Torrinhas
et al. 2013 [92]
Gastrointestinal surgery Pre-operative FO (Omegaven®)
(n ¼ 31)
3 d pre-surgery SO/MCT (Lipovenoes®)
(n ¼ 32)
No effect on post-operative infections, length of
ICU or hospital stay.
Tsekos et al. 2004 [100] Gastrointestinal surgery Perioperative SO/MCT þ FO (Omegaven®)
(n ¼ 53) vs Post-operative SO/MCT þ FO
(Omegaven®) (n ¼ 86)
2e3 d pre-surgery
followed by 5
d post-surgery
SO/MCT (brand un-disclosed)
(n ¼ 110)
Perioperative:
Y Mortality
Y Number of patients requiring ventilation
Y Hospital stay
No change in length of ICU stay
Umpierrez et al. 2012 [84] Surgery OO/SO (ClinOleic®)
(n ¼ 51)
28 d post-surgery SO (Intralipid®)
(n ¼ 49)
No difference in mortality, infections or length
of stay
Wachtler et al. 1997 [207] Gastrointestinal surgery SO/MCT/FO (Prototype of Lipoplus®)
(n ¼ 19)
5 d post-surgery SO/MCT (brand un-disclosed)
(n ¼ 21)
Trend toward fewer infections and shorter ICU
stay.
No effect on length of hospital stay
Wang et al. 2012 [104] Gastrointestinal surgery SO/MCT/FO (Lipoplus®)
(n ¼ 32)
5 d post-surgery SO/MCT (Lipofundin®)
(n ¼ 31)
Y Total bilirubin
Weiss et al. 2002 [90] Surgery Peri-operative FO (Omegaven®) (n ¼ 12) d-1 to d 5 SO (Lipovenoes®) (n ¼ 12) Y Length of hospital stay.
No effect on infection rate or mortality.
Wichmann et al. 2007 [96] Gastrointestinal surgery SO/MCT/FO (Lipoplus®)
(n ¼ 127)
5 d post-surgery SO (Intralipid®)
(n ¼ 129)
Y Length of hospital stay.
Trend toward fewer infections and decreased
length of ICU stay.
No effect on mortality
Wu et al. 2014 [110] Gastrointestinal surgery SO/MCT/OO/FO (SMOFlipid®) (n ¼ 20) 5 d post surgery MCT/SO (Lipovenoes®)
(n ¼ 15)
No difference in infections, duration of hospital
stay or mortality
Zhu et al. 2012 [93] Elderly gastrointestinal
surgery
SO þ FO (Intralipid® þ Omegaven®)
(n ¼ 29)
7 d post-surgery SO (Intralipid®) (n ¼ 28) Y Infectious complications
Y SIRS
Y Length of hospital stay
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Table 6
Clinically relevant outcomes from including different lipid emulsions in PN in critically ill medical patients.
Study Population Intervention Duration Control Outcome
Barbosa et al. 2010
[119]
Critically ill
with
sepsis/SIRS
SO/MCT/FO (Lipoplus®)
(n ¼ 13)
5 d SO/MCT (part of
LipidSpecial®)
(n ¼ 10)
[ PO2/FiO2 ratio
Y Length of hospital stay for surviving
patient sub-group.
No difference in ventilation days, length of
ICU stay or mortality
Barros et al. 2013,
2014 [208,209]
Elderly ICU
patients
on EN
Supplementary FO
(Omegaven®)
(n ¼ 15)
6 h infusions/d
for 3 d
No supplementary PN
(n ¼ 25)
[ Gas exchange
Trend toward shorter length of mechanical
ventilation and decreased mortality.
No effect on liver function
Burkhart et al. 2014
[120]
Sepsis FO (Omegaven®) (n ¼ 25) 7 d Standard care (n ¼ 25) No difference in duration of ICU stay or
mortality
Edmunds et al.
2014 [115]
Mechanically
ventilated
critically ill
FO-enriched lipids (SMOFlipid®,
Lipoplus® or Omegaven®)
(n ¼ 19)
OO/SO (ClinOleic®) (n ¼ 74)
5 d SO-based lipids (various
brands) (n ¼ 223)
Lipid-free (n ¼ 70)
SO/MCT (various brands)
(n ¼ 65)
For FO-enriched lipids:
Y Duration of mechanical ventilation
Y Length of ICU stay
Y Mortality
Friesecke et al.
2008 [126]
Medical ICU SO/MCT þ FO
(Lipofundin® þ Omegaven®)
(n ¼ 63)
6 d SO/MCT (Lipofundin®)
(n ¼ 60)
No effect on infection, duration of
mechanical ventilation, length of ICU stay or
28-day mortality
García-de-Lorenzo
et al. 2005 [210]
Severe burns OO/SO (ClinOleic®) (n ¼ 11) 6 d SO/MCT (Lipofundin®)
(n ¼ 11)
No effect on organ dysfunction,
requirement for ventilation, number of
infections, length of ICU or hospital stay or
mortality
Grau-Carmona
et al. 2015 [123]
Medical and
surgical ICU
SO/MCT/FO (Lipoplus®) (n¼ 58) 5 d SO/MCT (Lipofundin®)
(n ¼ 59)
Y Nosocomial infections
No difference in duration of ventilation,
length of ICU or hospital stay or 6-month
mortality
Gupta et al. 2011
[211]
ARDS on EN Supplemental FO (Omegaven®)
(n ¼ 31)
14 d Standard EN (n ¼ 30) No difference in duration of ventilation, ICU
stay or hospital stay or mortality
Hall et al. 2014
[118]
Critically ill
with sepsis
FO (Omegaven®)
(n ¼ 30)
14 d or to
discharge
Standard care (N ¼ 30) Y SOFA
Y Mortality in less severe sepsis subgroup
No effect on length of stay
Khor et al. 2011
[121]
Severe sepsis FO (Omegaven®)
(n ¼ 14)
5 d Saline (n ¼ 13) No effect on length of ICU or hospital stay
Mayer et al. 2003
[122]
Septic shock FO (Omegaven®)
(n ¼ 10)
5 d SO (Lipoven®) (n ¼ 11) No effect on mortality or length of
mechanical ventilation
Mayer et al. 2003
[117]
Septic shock FO (Omegaven®)
(n ¼ 5)
10 d SO (Lipoven®) (n ¼ 5) Trend toward shorter ventilation time.
No mortality in either group
Sabater et al. 2008
[212]
ARDS SO/MCT/FO (Lipoplus®) (n ¼ 8) 12 h SO (Intralipid®) (n ¼ 8) No effect on gas exchange or mortality
Wang et al. 2008
[116]
Acute
pancreatitis
SO þ FO
(Lipovenoes® þ Omegaven®)
(n ¼ 20)
5 d SO (Lipovenoes®) (n ¼ 20) Y Requirement for renal replacement
therapy
[ Oxygenation index
Trend toward fewer infections and shorter
length of ICU and hospital stay
Zhu et al. 2012 [98] Liver
transplantation
FO (Omegaven®)
(n ¼ 33)
7 d
post-surgery
SO/MCT (20% emulsion
with a 1:1 ratio)
(n ¼ 33)
Y Length of hospital stay
SOFA, Sequential Organ Failure Assessment.
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of sepsis. The newer composite SO/MCT/OO/FO (30:30:25:15) LE
has also shown a liver-protecting effect in post-operative patients
requiring PN, resulting in significantly lower ALT, AST and a-GST
compared with OO/SO [107].
This liver-protective effect has also been demonstrated in liver
transplantation patients, whereby post-operative FO-enriched PN
lowered ALT and prothrombin time as well as length of hospital
stay compared with PN containing SO/MCT [98]. Improvement in
liver injury and a reduction in the number of infectious morbidities
were also reported for the FO-enriched PN group.
It is important to note that not all clinical studies in surgical ICU
patients have been positive. Parenteral SO/MCT/OO/FO adminis-
tered to gastric cancer surgical patients resulted in no difference in
efficacy, safety, tolerance or clinical outcomes (including post-
operative complications) compared with SO/MCT [108]. Metry
et al. also found no difference in ventilation requirement, duration
of ICU or hospital stay or mortality following 7 days of post-
operative administration of parenteral SO/MCT/OO/FO comparedPlease cite this article in press as: Calder PC, et al., Lipids in the intensive
Nutrition (2017), http://dx.doi.org/10.1016/j.clnu.2017.08.032to SO alone [109]. Furthermore, Wu et al.'s study in gastrointestinal
surgery patients found no difference in inflammatory markers (C-
reactive protein, IL-6, IL-10, TNF-a and transforming growth factor
b1) or markers of oxidative stress compared with SO/MCT [110].
A meta-analysis of 6 RCTs (306 surgical patients) did conclude
that SO/MCT/OO/FO was associated with lower hepatic enzymes,
low-density lipoprotein, triglycerides and C-reactive protein
following post-operative administration compared with SO, but
found no statistically significant changes compared with SO/MCT
[111]. There was no difference in adverse events or length of hos-
pital stay compared with either SO or SO/MCT.
Eicosanoids are involved in the control of platelet aggregation
and so influence blood clotting and bleeding time. TXA2 and
prostacyclin (PGI2) are both produced from the omega-6 PUFA ARA.
TXA2 is pro-aggregatory and PGI2 is anti-aggregatory. EPA from FO
decreases the ARA content of the platelet membrane [112], so
decreasing production of both TXA2 and PGI2 [112]. Instead, pro-
duction of the EPA-derived eicosanoids TXA3, which is a weak
platelet aggregator, and PGI3 which is a potent inhibitor of plateletcare unit: Recommendations from the ESPEN Expert Group, Clinical
Table 7
Clinical and biochemical outcomes from including different lipid emulsions in PN in pediatric patients.
Study Population Intervention Duration Control Outcome in intervention group
Beken et al. 2014
[159]
Very low birth
weight preterm
infants
SO/MCT/OO/FO
(SMOFlipid®)
(n ¼ 40)
Mean: 14 d SO (Intralipid®)
(n ¼ 40)
Y Retinopathy of prematurity
No difference in morbidity or mortality
outcomes
D'Ascenzo et al.
2014 [160]
Very low birth
weight preterm
infants
SO/MCT/OO/FO
(SMOFlipid®)
(n ¼ 30)
7 d following birth SO (Intralipid®)
(n ¼ 32)
[ Plasma EPA and DHA
Y Plasma ARA
[ Serum triglycerides, plasma
phospholipids, free cholesterol
No difference in weight.
Deshpande et al.
2014 [161]
Preterm neonates SO/MCT/OO/FO
(SMOFlipid®)
(n ¼ 17)
7 d OO/SO (ClinOleic®)
(n ¼ 17)
[ RBC EPA
[ Vitamin E
Y F2 isoprostanes
Larsen et al. 2012
[166]
Infants undergoing
open heart surgery
SO/MCT/FO (Lipoplus®)
(n ¼ 16)
1-4 d before and
10 d post-surgery
SO (Intralipid®)
(n ¼ 16)
Y TNF-a
No difference in clinical outcomes
Larsen et al. 2015
[165]
Infants undergoing
open heart surgery
SO/MCT/FO (Lipoplus®)
(n ¼ 16)
3 d pre-op and 5 d
post-op
SO (Intralipid®)
(n ¼ 16)
[ Plasma phospholipid EPA
Y Plasma LTB4 and lymphocytes
Pawlik et al. 2013
[162]
Very low
birthweight
preterm infants
OO/SO þ FO
(ClinOleic® þ Omegaven®)
(n ¼ 60)
28 d OO/SO (ClinOleic®)
(n ¼ 70)
[ Plasma DHA
Y Cholestasis
Savini et al. 2013
[163]
Very low
birthweight
preterm infants
SO (Intralipid®) (n ¼ 30) vs
SO/MCT (Lipofundin®)
(n ¼ 30) vs SO/MCT/FO
(Lipidem®) (n ¼ 27) vs
OO/SO (ClinOleic®) (n ¼ 29)
vs SO/MCT/OO/FO
(SMOFlipid®) (n ¼ 28)
21 d e Lowest plasma phytosterols in
SMOFlipid® group
No difference in liver function
Vlaardingerbroek
et al. 2014 [158],
Roelands et al.
2016 [134]
Very low birth
weight infants
SO/MCT/OO/FO
(SMOFlipid®)
(n ¼ 48)
Median: 11 d SO (Intralipid®)
(n ¼ 48)
[ Plasma EPA and DHA
[ Weight gain
No difference in ARA.
No differences in morbidity, mortality
or other biochemical outcomes
No difference in neurodevelopmental
outcome
Wang et al. 2016
[164]
Preterm infants OO/SO (ClinOleic®) (n ¼ 50) 14 d SO (Intralipid®)
(n ¼ 50)
YDirect bilirubin
Differences in bile acid composition
No difference in clinical outcome
P.C. Calder et al. / Clinical Nutrition xxx (2017) 1e1810aggregation occurs [112]. Thus, FO results in decreased platelet
aggregation [112], which can increase bleeding and time to clotting.
With regard to this theoretical increased risk of bleeding with FO-
based PN, studies to date have shown that FO is safe to include in
PN regimens and does not increase risk of bleeding. Acute pre-
treatment with omega-3 PUFAs in coronary artery bypass graft
patients non-significantly affected the activity of platelets and did
not influence postoperative blood loss [113].
Based on the evidence available and according to the new ESPEN
guidelines on clinical nutrition in surgery, postoperative PN
including omega-3-fatty acids should be started only in malnour-
ished patients who cannot be adequately fed enterally and, there-
fore, require PN [114]. If PN is required post-operatively in the ICU,
2nd or 3rd generation lipid emulsions may be administered, and in
the case of surgical complications, FO-containing PN is
recommended.
4.4.2. Fish oil-enriched PN in non-surgical ICU patients
Compared to SO and SO/MCT, FO-enriched PN may provide
clinical benefits for a wide range of ICU patients. In mechanically
ventilated critically ill patients, FO-enriched PN resulted in a
shorter duration of mechanical ventilation and a faster time to ICU
discharge compared to lipid-free or SO-based PN [115]. In patients
with acute pancreatitis, administration of FO-supplemented PN
resulted in significantly decreased CRP in addition to better
oxygenation index and fewer days of continuous renal replacement
therapy compared with SO alone [116].
Clinical studies in patients with sepsis have shown that paren-
teral administration of either omega-6 or omega-3 fatty acids re-
sults in elevated concentrations of the respective free fatty acidsPlease cite this article in press as: Calder PC, et al., Lipids in the intensive
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[117]. Hence PN containing FO should theoretically lead to
increased levels of inflammation-resolving resolvins and associated
clinical benefits. The latter is supported by some trials. Compared to
standard care, FO administered to patients with sepsis resulted in a
significant reduction in new organ dysfunction and lower
maximum C-reactive protein concentrations [118]. A significant
reduction in mortality was observed for patients with less severe
sepsis. Furthermore, FO-enriched PN (SO/MCT/FO 50:40:10)
administered to patients with sepsis or SIRS for 5 days increased
plasma EPA levels, decreased plasma IL-6, improved oxygenation
(PO2/FiO2 ratio) and reduced length of hospital stay compared to
SO/MCT [119]. However, several studies have failed to show any
clinical benefit of FO-enriched PN in cases of sepsis or septic shock
compared to either standard care, saline or SO-based PN
[117,120e122], although one of these studies did find a non-
statistically significant trend toward shorter ventilation time [117].
FO-enriched PN administered to critically ill medical and sur-
gical patients may result in a significant reduction in the number of
nosocomial infections compared to SO/MCT [123]. Time free of
infection was also significantly longer in the FO-supplemented
group, although there was no effect reported for ICU or hospital
stay or 6-month mortality rate.
This lack of effect of FO-enriched PN onmortality rate compared
to standard PN is confirmed bymeta-analyses of 6 RCTs [124] and of
8 RCTs [125] in critically ill adults, the latter also finding no dif-
ference in infectious complications or ICU length of stay. There was
weak evidence of a reduction of hospital length of stay associated
with FO-enriched PN, but this was strongly influenced by one small
study [125].care unit: Recommendations from the ESPEN Expert Group, Clinical
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ill patients report positive outcomes. Administration of FO-
enriched PN to medical ICU patients (with and without SIRS) had
no effect on inflammatory markers (IL-6), incidence of infection,
duration of mechanical ventilation, length of ICU stay or 28-day
mortality compared with SO/MCT [126]. The study included
severely ill patients that were at different stages of the inflamma-
tion/inflammation resolution cycle; hence the intervention may
have been administered after termination of the initial inflamma-
tory process in some patients. Timing of omega-3 fatty acid
administration is important if hyper-inflammation is to be pre-
vented, and from previously discussed studies, administration prior
to commencement of inflammation is likely optimal. Furthermore,
dosage levels of the administered FO also play a critical role in
whether the intervention provides clinical benefit. A study inves-
tigating the dose-dependent effects of FO-enriched PN in a range of
ICU patients found that the most favorable effects on survival,
infection rates and length of hospital stay occurred when paren-
teral FO was administered between 0.1 and 0.2 g/kg/d. A 26% lower
antibiotic demand was associated with parenteral administration
of FO between 0.15 and 0.20 g/kg/d [127].
5. Lipids and PN in pediatric patients
The joint European Society for Paediatric Gastroenterology,
Hepatology and Nutrition (ESPGHAN) and ESPEN guidelines on PN
in pediatrics recommend that in small preterm infants, when EN is
not possible, PN including lipids should be initiated as soon as
possible after birth [128]. Intolerance to full EN is common in
preterm infants, and results in a high incidence of postnatal growth
failure.
Surveys of current practice in neonatal ICUs in Europe and the
US show that there is a wide range in the timing and initial dose of
lipid administration [129]. In the UK and Ireland, whilst a greater
proportion of preterm infants start PN within 48 h, around one
quarter of preterm infants still are not given PN until or after day 3
[130]. When considering a role for PN and lipids in preterm infants,
the potential to improve neurodevelopmental outcomes should not
be overlooked: DHA is critical in neurodevelopment with the brain
comprising 60% of lipid, and with >80% of brain DHA accumulating
between 26 and 40 weeks gestation [131].
In preterm infants, there is concern regarding early lipid-
containing PN and the risk of complications such as sepsis, bron-
chopulmonary dysplasia (BPD), hyperbilirubinemia, liver disease,
persistent pulmonary hypertension of the newborn (PPHN) and
thrombocytopenia. However, a meta-analysis of 14 studies inves-
tigating the effect of early (2 d) parenteral lipid in very low birth
weight (VLBW) infants, found no difference in sepsis, BPD, growth
or mortality rates compared to later (2 d) administration [132].
This is supported by a later RCT comparing lipid-containing PN
administered from birth to VLBW infants with standard PN from
birth with lipids administered 2 d later, which reported no differ-
ence in growth, biochemical or clinical outcomes between the
groups [133,134].
There is also a risk of hypertriglyceridemia associated with lipid
administration in preterm infants, due to limited fat and muscle
mass and thus decreased hydrolytic capacity from lipoprotein
lipase. Whilst there is no specific indicator of lipid tolerance, as
plasma triglyceride levels indicate plasma clearance, monitoring of
plasma triglycerides is recommended. ESPGHAN recommends a
safe triglyceride level of 2.85 mmol/l (250mg/dl) in preterm infants
and newborns [128], whilst ASPEN recommends 2.26 mmol/l
(200 mg/dl) [135]. However, in one trial, hypertriglyceridemia of
>3 mmol/l (>265 mg/dl) was not associated with neonatal mor-
bidities [133].Please cite this article in press as: Calder PC, et al., Lipids in the intensive
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incidence is directly related to TPN duration. Short bowel syndrome
(SBS) accounts for 1.4% of all deaths for children under 4 y and is
primarily related to the development of IFALD which is identified
through biochemical parameters such as direct bilirubin levels
>2 mg/dl (34 mmol/l), increased GGT, ALT, and serum bile acids
[136,137]. Some 40e60% of patients with short bowel syndrome on
TPN develop cholestasis, and a study published in 2005 reported
that the mortality rate is approximately 78% if bilirubin remains
>3 mg/dl for 3 months, and increases to 90% if cholestasis is diag-
nosed and there is noweaning off TPNwithin a year of diagnosis, or
failure to receive a liver transplant [138]. A Pediatric Intestinal
Failure Consortium (PIFCon) retrospective analysis of clinical
outcome data for infants with intestinal failure reported that of a
cohort of 272 infants (<1 y old and on prolonged TPN for >2
months), the mortality rate was 27% and intestinal transplantation
rate was 26% [139].
Besides prematurity and prolonged TPN use, other risk factors
for IFALD include lack of enteral nutrition, multiple operative pro-
cedures, sepsis or inflammation, and possibly also nutrient de-
ficiencies or toxicities associated with other components in lipid PN
[140,141]. Preventative/treatment measures for IFALD may include
cycling PN, feed advancement, prevention and aggressive treat-
ment of sepsis, lipid reduction to1 g/kg/d, altering the lipid being
used in PN (see below), elimination of hepatotoxic medications,
reduction of bacterial overgrowth, use of the bile acid ursodiol,
reduction of transfusions and minimizing surgical procedures if
possible [137,142e151], although the evidence in favor of some of
these is weak [152]. Whilst IFALD/cholestasis may be reversed with
elimination/reduction of lipids, cholestasis may be progressive
whilst on PN. It may lead to liver cirrhosis, liver failure, liver
transplant or death [153].
Regarding the choice of LE in PN for pediatric patients, it is
suggested that high levels of omega-6 PUFAs and phytosterols
found in SO can be hepatotoxic and lead to IFALD [154]. Phytos-
terols have been shown to antagonize the farnesoid-X-receptor
(FXR) [155] which normally acts to suppress hepatic lipogenesis
and bile acid synthesis. Thus, in the presence of phytosterols, those
processes continue uncontrolled leading to both fatty liver and
cholestasis. FO-containing PN may have a protective effect against
IFALD due to the lower phytosterol content, higher omega-3 PUFA
content, and higher a-tocopherol content, and to direct regulation
of bile flow through eicosanoid-mediated mechanisms [156]. In
pediatric patients with IFALD whose cholestasis was resolved with
use of FO, decreased direct bilirubin levels and markers of liver
injury were reported together with improvement in hepatic func-
tion [156,157]. However, some of these studies compared a group of
infants receiving FO-based PN with an historic control group.
Furthermore, some studies used pure FO LE rather than a lipid mix.
Finally, many studies have lowered the lipid dose being used
(generally to 1 g/kg/d) at the same time as introducing FO-
containing PN. Thus, it is difficult to disentangle the effects of the
lower lipid dose from those of an alternative lipid mixture.
With regard to other potential clinical benefits of FO-enriched
PN in preterm infants, an RCT in VLBW infants administered SO/
MCT/OO/FO reported a significant increase in weight gain and
increased plasma EPA and DHA (but no difference in ARA)
compared to SO-based PN [134,158]. However, there were no dif-
ferences in morbidity, mortality or biochemical outcomes between
the two groups. Several studies concur regarding these outcomes
with multi-component lipid PN versus other LEs [158e164].
FO-enriched PN given to infants undergoing major cardiac sur-
gery may help ameliorate the post-operative inflammatory
response. A study investigating the effects of parenteral SO/MCT/FO
(40:50:10) given pre- and post-operatively to infants undergoingcare unit: Recommendations from the ESPEN Expert Group, Clinical
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surgery compared with SO alone [165]. Specifically the FO con-
taining LE resulted in higher plasma phospholipid EPA and
decreased plasma LTB4 and lymphocytes. An earlier trial also found
significantly lower TNF-a concentrations and a positive association
with length of hospital stay in the SO/MCT/FO group compared
with SO when given perioperatively in infants undergoing cardiac
surgery [166].
In summary, for preterm infants, lipids given directly following
birth at 2 g/kg/d appear safe according to short term studies.
Emulsions with a mix of lipid sources including FO may offer
benefits over SO alone, although long-lasting positive effects need
to be proven.
6. Economic considerations for fish oil-enriched lipids in the
ICU
Pradelli et al. performed an analysis of the cost-effectiveness of
SO/MCT/OO/FO in surgical and ICU patients in four European
countries (Italy, Germany, France and the UK) [167]. The analysis
considered costs associated with nutritional treatment, ICU stay,
general ward stay and nosocomial infections as well as the benefits
of FO-containing PN on infection rates and length of stay. The study
concluded that the treatment costs associated with FO-enriched PN
were completely offset by the savings made from the subsequent
reduction in hospital stay and reduced antibiotic costs. Hence, FO-
containing PN is cost-effective and beneficial for both ICU and non-
ICU patients in hospitals in Italy, Germany, France and the UK
compared with standard PN.
7. Future directions
7.1. Effects of omega-3 fatty acids in preclinical models of acute
neurological injury
Spinal cord injury (SCI) is associated with significant social and
healthcare burden [168]. In the acute phase following SCI, the initial
lesion expands and results in a secondary injury wave, reflected in
the progressive loss of gray matter within the spinal cord [169,170].
Secondary injury pathophysiology is characterized by activation of
inflammatory pathways, increased glutamate release and vascular
damage leading to ischemia [171]. Preclinical studies involving
rodent compression and hemisection SCI models, at thoracic and
cervical levels, have demonstrated that acute DHA injection in the
range of 250e500 nmol/kg body weight, with or without sustained
dietary supplementation, has a neuroprotective effect and im-
proves neurological outcomes [172e177]. Specifically, DHA
administration results in a reduced lesion size and less inflamma-
tion (including TNF-a expression), reduced neuronal, oligoden-
drocyte and neurofilament loss, reduced macrophage/microglia
recruitment and activation, and less apoptotic death, and this is
correlated with an improved locomotor recovery [172e176]. DHA
appears to enhance motor function recovery via its effect on the
serotonin fiber input on motor neurons [177]. DHA also has a
positive effect on synaptic remodeling and may enhance synapto-
genesis. Immunoreactivity of synaptophysin, a synaptic vesicle
protein, was found to be less reduced after injury in DHA-treated
animals comparedwith controls, in a rat model of cervical SCI [177].
With regard to traumatic brain injury (TBI), in the US there are
1.5e2 million new cases per year, accounting for 30% of injury-
related deaths, with an annual cost of $25 billion [178]. TBI,
particularly repetitive, increases susceptibility to Alzheimer's dis-
ease, as evidenced in murine models, where repetitive TBI resulted
in increased amyloid b-deposition, isoprostanes and cognitive
impairment [179]. However, acute DHA administration (500 nmol/Please cite this article in press as: Calder PC, et al., Lipids in the intensive
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improve spatial memory [180]. In terms of the mechanisms
involved, TBI and SCI are both associated with glutamate overflow
which may be controlled via omega-3 PUFA through inhibition of
voltage-sensitive Naþ and Ca2þ channels and activation of Kþ
channels [181].
DHA may also be a future treatment option for patients with
stroke. In rodent ischemic stroke models, DHA administration,
acting via biosynthesis of neuroprotectin D1 (aka protectin D1),
reduces astrocyte and neuronal cell death and promotes cell sur-
vival, resulting in significantly reduced total infarct volume
[182,183].
Preclinical rodent models have also shown that the improved
neurological outcome following acute DHA injection is not only
associated with neuronal survival. Indeed, controlled cortical
impact models in mice have demonstrated that ablation of astro-
cytes resulted in decreased neuronal survival, and increased neu-
roinflammation [184]. Hence, a subset of astrocytes appears to have
a role in aiding neuronal survival and reducing inflammation after
brain injury [185]. It has also been demonstrated that after mild
compression injury in mice, heterogeneity of microglia at the site
develops alongside a coordinated microglial response [186].
Following TBI, there is upregulation of a sub-population of micro-
glia that express galectin-3/MAC-2 lectins that are involved in
myelin degradation [187]. Hence the acute DHA administration
appears to play a role in modulating this complex glial response,
e.g. by increasing these new and proliferating microglia and as-
trocytes, and ultimately resulting in decreased lesion volume.
In humans, following a single TBI, there is evidence of persistent
neuroinflammation and microglial activation for up to 17 years
afterward [188,189]. This suggests that interventions using DHA
may be appropriate for a longer time period following TBI rather
than just in the acute phase.
In summary, preclinical models of SCI and TBI suggest that DHA,
if administered in the acute phase and for some time afterward,
may help to limit progression of neurological injury and improve
neurological outcomes.
7.2. Effects of omega-3 fatty acids in preclinical models of sepsis
and tissue injury
Omega-3 fatty acids have been shown to have a protective effect
against edema formation in a model of septic lung failure due to the
increased generation of LTB5. In perfused rabbit lung treated with
Escherichia coli hemolysin, EPA suppressed vascular permeability
and shifted leukotriene formation from the 4-series to the 5-series
compared to ARA [190]. Hence, the composition of LEs used in PN
may influence microvascular changes induced by bacterial toxins.
The favorable lipid mediators formed from EPA may also have a
beneficial effect on pulmonary hypertension compared to those
formed from ARA. In a rabbit lung model of acute pulmonary hy-
pertension investigating the pulmonary vasoconstrictor potencies
of EPA and ARA, EPA resulted in an almost 2-fold decrease in pul-
monary hypertension compared to ARA [191]. EPA is metabolized
to PGI3 and TXA3 and it may be that the dominant presence of TXA3
mediates EPA's weaker pulmonary vasoconstrictor effects,
compared with ARA and ARA-derived TXA2.
In inflammatory conditions, particularly systemic inflammation
with sepsis and multi-organ failure, the transmigration of mono-
cytes through the vascular endothelium is an important contrib-
uting factor to the pathogenesis of the condition. In an in vitro
experiment investigating the effect of different free fatty acids on
TNF-a activated human umbilical vein endothelial cells, EPA and
DHA (but not ARA), resulted in markedly suppressed platelet-
activating factor (PAF), resulting in reduced monocyte rolling andcare unit: Recommendations from the ESPEN Expert Group, Clinical
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work has suggested that the binding of endothelial PAF and the PAF
receptor on leukocytes are responsible for the adhesive interactions
of monocytes followed by their activation [193]. This mechanism
involving PAF may be one factor responsible for the inflammation-
dampening effect of EPA and DHA.
In a murine model of acute inflammation, pre-infusion of FO-
rich LE resulted in reduced leukocyte invasion and reduced TNF-a
production in the alveolar space following intra-tracheal LPS
challenge, compared with SO or saline [194]. In PAF-receptor
knock-out mice, the different effects of FO and SO were far less
marked. This supports the hypothesis that the anti-inflammatory
effect of FO is dependent on PAF/PAF-receptor linked signaling.
Similarly, in a murine model of ARDS, pre-infusion with FO-
containing LE resulted in greater reduction of leukocyte invasion
and protein leakage into the alveolar space than either SO or SO/
MCT [195]. These results suggest that the reduction in the pro-
portion of omega-6 PUFA administered may help improve lung
injury.
Extensive lymphocytic apoptosis is a hallmark feature of late-
stage sepsis, and can be clearly seen in the spleen as well as
other organs [196]. In a murine model of endotoxin-induced ALI,
OO pre-infusion resulted in less mortality compared with SO pre-
infusion [197]. Fewer lymphocytes were observed in the spleen in
the SO group which appeared to be due to increased apoptosis and
necrotic cell death, although both LEs resulted in increased lym-
phocytic apoptosis via intrinsic pathways. Hence, OO-based LEs
may have fewer deleterious immunological effects than SO, at least
in murine models of ALI.
In critically ill patients, a reduced flow of blood to the gut can
lead to intestinal ischemia, decreased barrier function and
increased bacterial translocation. A rat endotoxin model investi-
gating the effects of different lipid pre-infusions on microcircula-
tion and intestinal barrier function reported improved blood flow
to the intestine and less viable bacteria detected in the mesenteric
lymph nodes and liver following endotoxin challenge with FO-
supplemented SO/MCT compared with SO/MCT or SO alone [198].
The reduction in viable bacteria is thought to be related to
improved killing of translocated bacteria rather than a reduction in
translocation.
In healthy human volunteers, infusion of FO blunted the
endotoxin-induced inflammatory response including suppression
of monocyte generation of pro-inflammatory cytokines (TNF-a, IL-
1, IL-6 and IL-8), and inhibition of monocyte-endothelium adhesion
and transendothelial monocyte migration compared to SO [199].
Decreased fever in response to LPS, reduced TNF-a synthesis and a
reduced LPS-induced neuroendocrine response (ACTH and
noradrenaline) have also been observed with FO infusion in
humans [200]. Similar protective results have been found after pre-
infusion of either SO- or FO-based lipid emulsions and subsequent
LPS-inhalation [201].
In summary, from preclinical models, different lipids may
impact the inflammatory response of critically ill patients. SO LEs
may exert negative effects in terms of increased pro-inflammatory
cytokines and immune depression, such as lymphocyte destruc-
tion, whereas FO appears to dampen the inflammatory response
and improve pre-clinical outcomes.
8. Conclusion
Lipids are an important component of enteral and parenteral
nutrition and provide essential fatty acids, a concentrated source of
calories and building blocks for cell membranes. Whilst LA-rich
vegetable oil-based enteral and parenteral nutrition is still widely
used, newer lipid components such as MCTs and OO appear to bePlease cite this article in press as: Calder PC, et al., Lipids in the intensive
Nutrition (2017), http://dx.doi.org/10.1016/j.clnu.2017.08.032safer and better tolerated than pure SO. FO-enriched enteral and
parenteral nutrition appears to be well tolerated and confers
additional clinical benefits, particularly in surgical ICU patients, due
to its anti-inflammatory and immune-modulating effects. Whilst
the evidence base is not conclusive, there appears to be a potential
for FO-enriched nutrition, particularly administered peri-
operatively, to reduce the rate of complications and ICU and hos-
pital stay in surgical ICU patients, as well as to improve complica-
tions such as IFALD associated with SO-based LEs. The evidence for
FO-based nutrition in non-surgical ICU patients is less clear
regarding its clinical benefits and additional, well-designed large-
scale clinical trials need to be conducted in this area.
Whilst FO-based PN can be more expensive than other available
LEs, cost-benefit analysis has shown that the treatment costs for
ICU patients are completely offset by the savings made from the
subsequent reduction in hospital stay and reduced antibiotic costs.
Future directions regarding FO-based enteral and parenteral
nutrition may include its use in TBI and SCI, as well as in compli-
cations relating to sepsis and tissue injury, following the success of
such interventions in preclinical models.
Conflicts of interest
P.C.C. has received speaking and advisory honoraria from
Fresenius-Kabi, B. Braun, Baxter Healthcare, Abbott Nutrition and
Danone/Nutricia. M.A. has received speaking honoraria from B.
Braun, Cosmed and Danone/Nutricia. N.E.D. has received speaking
and advisory honoraria from Abbott Nutrition. T.G. has received
speaking honoraria from B. Braun and Fresenius-Kabi. S.K. has
received speaking honoraria from Fresenius-Kabi, B. Braun, Baxter
Healthcare, Nutricia Poland, Nestle and Shire. S.L has received
speaking honoraria from Fresenius-Kabi, Baxter Healthcare and
Abbott Nutrition, K.M. has received speaking honoraria from
Fresenius-Kabi, B. Braun, Baxter Healthcare, Abbott Nutrition, and
Nestle. A.M-T. has received grant funding from B. Braun. L.P. has
received speaking honoraria and grants from Fresenius-Kabi,
Amgen, CSL Behring, Gilead Sciences, GlaxoSmithKline, Janssen-
Cilag, Novartis, Roche, Sorin Group, and Viiv Healthcare. M.P.
holds an issued patent on the treatment of parenteral nutrition-
associated liver disease: a license agreement for the use of Ome-
gaven has been signed by Boston Children's Hospital and Fresenius
Kabi. P.S. has received speaking honoraria and grants from
Fresenius-Kabi, B. Braun, Baxter Healthcare and Abbott Nutrition.
J.K.I. and H.V. have no conflicts to declare.
References
[1] Singer P, Hiesmayr M, Biolo G, Felbinger TW, Berger MM, Goeters C, et al.
Pragmatic approach to nutrition in the ICU: expert opinion regarding which
calorie protein target. Clin Nutr 2014;33:246e51. http://dx.doi.org/10.1016/
j.clnu.2013.12.004.
[2] Alkhawaja S, Martin C, Butler RJ, Gwadry-Sridhar F. Post-pyloric versus
gastric tube feeding for preventing pneumonia and improving nutritional
outcomes in critically ill adults. Cochrane Database Syst Rev 2015;8. http://
dx.doi.org/10.1002/14651858.CD008875.pub2. CD008875.
[3] Kreymann KG, Berger MM, Deutz NEP, Hiesmayr M, Jolliet P, Kazandjiev G,
et al. ESPEN guidelines on enteral nutrition: intensive care. Clin Nutr
2006;25:210e23. http://dx.doi.org/10.1016/j.clnu.2006.01.021.
[4] McClave SA, Martindale RG, Vanek VW, Mccarthy M, Roberts P, Taylor B,
et al. Guidelines for the provision and assessment of nutrition support
therapy in the adult critically ill patient: Society of Critical Care Medicine and
American Society for Parenteral and Enteral Nutrition. Crit Care Med
2009;37:1e30. http://dx.doi.org/10.1097/CCM.0b013e3181a40169.
[5] Reintam Blaser A, Starkopf J, Alhazzani W, Berger MM, Casaer MP, Deane AM,
et al. Early enteral nutrition in critically ill patients: ESICM clinical practice
guidelines. Intensive Care Med 2017;43:380e98. http://dx.doi.org/10.1007/
s00134-016-4665-0.
[6] Doig GS, Chevrou-Severac H, Simpson F. Early enteral nutrition in critical
illness: a full economic analysis using US costs. Clin Outcomes Res 2013;5:
429e36. http://dx.doi.org/10.2147/CEOR.S50722.care unit: Recommendations from the ESPEN Expert Group, Clinical
P.C. Calder et al. / Clinical Nutrition xxx (2017) 1e1814[7] McClave SA, Martindale RG, Rice TW, Heyland DK. Feeding the critically ill
patient. Crit Care Med 2014;42:2600e10. http://dx.doi.org/10.1097/
CCM.0000000000000654.
[8] Huynh D, Chapman M, Nguyen N. Nutrition support in the critically ill. Curr
Opin Gastroenterol 2013;29:208e15. http://dx.doi.org/10.1097/MOG.0b0
13e32835c9c83.
[9] Artinian V, Krayem H, DiGiovine B. Effects of early enteral feeding on the
outcome of critically ill mechanically ventilated medical patients. Chest
2006;129:960e7. http://dx.doi.org/10.1378/chest.129.4.960.
[10] Doig GS, Heighes PT, Simpson F, Sweetman EA, Davies AR. Early enteral
nutrition, provided within 24 h of injury or intensive care unit admission,
significantly reduces mortality in critically ill patients: a meta-analysis of
randomised controlled trials. Intensive Care Med 2009;35:2018e27. http://
dx.doi.org/10.1007/s00134-009-1664-4.
[11] Doig GS, Heighes PT, Simpson F, Sweetman EA. Early enteral nutrition re-
duces mortality in trauma patients requiring intensive care: a meta-analysis
of randomised controlled trials. Injury 2011;42:50e6. http://dx.doi.org/
10.1016/j.injury.2010.06.008.
[12] Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al.
ESPEN guidelines on definitions and terminology of clinical nutrition. Clin
Nutr 2016;36:49e64. http://dx.doi.org/10.1016/j.clnu.2016.09.004.
[13] Singer P, Berger MM, Van den Berghe G, Biolo G, Calder P, Forbes A, et al.
ESPEN guidelines on parenteral nutrition: intensive care. Clin Nutr 2009;28:
387e400. http://dx.doi.org/10.1016/j.clnu.2009.04.024.
[14] Simpson F, Doig GS. Parenteral vs. enteral nutrition in the critically ill pa-
tient: a meta-analysis of trials using the intention to treat principle. Intensive
Care Med 2005;31:12e23. http://dx.doi.org/10.1007/s00134-004-2511-2.
[15] Casaer M, Mesotten D, Hermans G, Wouters P, Schetz M, Meyfroidt G, et al.
Early versus late parenteral nutrition in critically ill adults. N Engl J Med
2011;365:506e17. http://dx.doi.org/10.1056/NEJMoa1102662.
[16] Braunschweig CL, Levy P, Sheean PM, Wang X. Enteral compared with
parenteral nutrition: a meta-analysis. Am J Clin Nutr 2001;74:534e42.
[17] Heidegger CP, Berger MM, Graf S, Zingg W, Darmon P, Costanza MC, et al.
Optimisation of energy provision with supplemental parenteral nutrition in
critically ill patients: a randomised controlled clinical trial. Lancet 2013;381:
385e93. http://dx.doi.org/10.1016/S0140-6736(12)61351-8.
[18] Harvey SE, Parrott F, Harrison DA, Bear DE, Segaran E, Beale R, et al. Trial of
the route of early nutritional support in critically ill adults. N Engl J Med
2014;371:1673e84. http://dx.doi.org/10.1056/NEJMoa1409860.
[19] Calder PC. Functional roles of fatty acids and their effects on human health.
J Parenter Enteral Nutr 2015;39:18Se32S. http://dx.doi.org/10.1177/
0148607115595980.
[20] Paulsrud J, Pensler L, Whitten C, Stewart S, Holman R. Essential fatty acid
deficiency in infants induced by fat-free intravenous feeding. Am J Clin Nutr
1972;25:897e904.
[21] Wanten GJA, Calder PC. Immune modulation by parenteral lipid emulsions.
Am J Clin Nutr 2007;85:1171e84.
[22] Calder PC. Long-chain n-3 fatty acids and inflammation: potential applica-
tion in surgical and trauma patients. Braz J Med Biol Res 2003;36:433e46.
[23] Calder PC. Lipids for intravenous nutrition in hospitalised adult patients: a
multiple choice of options. Proc Nutr Soc 2013;72:263e76. http://dx.doi.org/
10.1017/S0029665113001250.
[24] Tribole E. What happened to do no harm? The issue of dietary omega-6 fatty
acids. Prostagl Leukot Essent Fat Acids 2009;80:78e9. http://dx.doi.org/
10.1016/j.plefa.2008.12.003.
[25] Holman RT. The slow discovery of the importance of omega-3 essential fatty
acids in human health. J Nutr 1998;128:427e33.
[26] Sailer D, Muller M. Medium chain triglycerides in parenteral nutrition.
J Parenter Enteral Nutr 1981;5:115e9.
[27] Ulrich H, Pastures SM, Katz DP, Kvetan V. Parenteral use of medium-chain
triglycerides: a reappraisal. Nutrition 1996;12:231e8. http://dx.doi.org/
10.1016/S0899-9007(96)00089-6.
[28] Lekka ME, Liokatis S, Nathanail C, Galani V, Nakos G. The impact of intra-
venous fat emulsion administration in acute lung injury. Am J Respir Crit
Care Med 2004;169:638e44. http://dx.doi.org/10.1164/rccm.200305-620OC.
[29] Sala-Vila A, Barbosa V, Calder P. Olive oil in parenteral nutrition. Curr Opin
Clin Nutr Metab Care 2007;10:165e74. http://dx.doi.org/10.1097/
MCO.0b013e32802bf787.
[30] Palova S, Charvat J, Kvapil M. Comparison of soybean oil- and olive oil-based
lipid emulsions on hepatobiliary function and serum triacylglycerols level
during realimentation. J Int Med Res 2008;36:587e93. http://dx.doi.org/
10.1177/147323000803600326.
[31] Edward R-R, Innes JK, Marino LV, Calder PC. Influence of different intrave-
nous lipid emulsions on growth, development and laboratory and clinical
outcomes in hospitalised paediatric patients: a systematic review. Clin Nutr
2017. http://dx.doi.org/10.1016/j.clnu.2017.07.003 (in press).
[32] Carpentier YA, Dupont IE. Advances in intravenous lipid emulsions. World J
Surg 2000;24:1493e7. http://dx.doi.org/10.1007/s002680010267.
[33] Hultin M, Müllertz A, Zundel M, Olivecrona G, Hansen T, Deckelbaum R, et al.
Metabolism of emulsions containing medium- and long-chain triglycerides
or interesterified triglycerides. J Lipid Res 1994;35:1850e60.
[34] Simoens C, Deckelbaum RJ, Carpentier YA. Metabolism of defined structured
triglyceride particles compared to mixtures of medium and long chain tri-
glycerides intravenously infused in dogs. Clin Nutr 2004;23:665e72. http://
dx.doi.org/10.1016/j.clnu.2003.11.004.Please cite this article in press as: Calder PC, et al., Lipids in the intensive
Nutrition (2017), http://dx.doi.org/10.1016/j.clnu.2017.08.032[35] Richelle M, Deckelbaum RJ, Vanweyenberg V, Carpentier YA. Lipoprotein
metabolism during and after a 6-h infusion of MCT/LCT vs LCT emulsion in
man. Clin Nutr 1997;16:119e23. http://dx.doi.org/10.1016/S0261-5614(97)
80237-3.
[36] Qi K, Seo T, Jiang Z, Carpentier YA, Deckelbaum RJ. Triglycerides in fish oil
affect the blood clearance of lipid emulsions containing long- and medium-
chain triglycerides in mice. J Nutr 2006;136:2766e72.
[37] Simoens CM, Deckelbaum RJ, Massaut JJ, Carpentier YA. Inclusion of 10% fish
oil in mixed medium-chain triacylglycerol-long-chain triacylglycerol emul-
sions increases plasma triacylglycerol clearance and induces rapid eicosa-
pentaenoic acid (20:5n-3) incorporation into blood cell phospholipids. Am J
Clin Nutr 2008;88:282e8.
[38] Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflam-
mation and immune responses by prostaglandins and thromboxanes. J Clin
Investig 2001;108:15e23. http://dx.doi.org/10.1172/JCI13416.
[39] Lewis RA, Austen K, Soberman RJ. Leukotrienes and other products of the 5-
lipoxygenase pathway: biochemistry and relation to pathobiology in human
diseases. N Engl J Med 1990;323:645e55. http://dx.doi.org/10.1056/
NEJM199009063231006.
[40] Vachier I, Chanez P, Bonnans C, Godard P, Bousquet J, Chavis C. Endogenous
anti-inflammatory mediators from arachidonate in human neutrophils.
Biochem Biophys Res Commun 2002;290:219e24. http://dx.doi.org/
10.1006/bbrc.2001.6155.
[41] Bitto A, Minutoli L, David A, Irrera N, Rinaldi M, Venuti FS, et al. Flavocoxid, a
dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflam-
matory response and protects mice from sepsis. Crit Care 2012;16:R32.
http://dx.doi.org/10.1186/1364-8535-16-R32.
[42] Walker J, Dichter E, Lacorte G, Kerner D, Spur B, Rodriguez A, et al. Lipoxin A4
increases survival by decreasing systemic inflammation and bacterial load in
sepsis. Shock 2011;36:410e6. http://dx.doi.org/10.1097/SHK.0b013e3
1822798c1.
[43] Calder PC. Marine omega-3 fatty acids and inflammatory processes: effects,
mechanisms and clinical relevance. Biochim Biophys Acta Mol Cell Biol Lipids
2015;1851:469e84. http://dx.doi.org/10.1016/j.bbalip.2014.08.010.
[44] Serhan C, Petasis N. Resolvins and protectins in inflammation resolution.
Chem Rev 2011;111:5922e43. http://dx.doi.org/10.1021/cr100396c.
[45] Ott J, Hiesgen C, Mayer K. Lipids in critical care medicine. Prostagl Leukot
Essent Fat Acids 2011;85:267e73. http://dx.doi.org/10.1016/j.plefa.2011.
04.011.
[46] Spite M, Norling LV, Summers L, Yang R, Cooper D, Nicos A, et al. Resolvin D2
is a potent regulator of leukocytes and controls microbial sepsis. Nature
2009;461:1287e91. http://dx.doi.org/10.1038/nature08541.
[47] Stanley JC, Elsom RL, Calder PC, Griffin BA, Harris WS, Jebb SA, et al. UK Food
Standards Agency Workshop Report: the effects of the dietary n-6:n-3 fatty
acid ratio on cardiovascular health. Br J Nutr 2007;98:1305e10. http://
dx.doi.org/10.1017/S000711450784284X.
[48] Harris WS. The omega-6/omega-3 ratio and cardiovascular disease risk: uses
and abuses. Curr Cardiovasc Risk Rep 2007;1:39e45.
[49] McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR,
Braunschweig C, et al. Guidelines for the provision and assessment of
nutrition support therapy in the adult critically ill patient: Society of Critical
Care Medicine (SCCM) and American Society for Parenteral and Enteral
Nutrition (A.S.P.E.N.). J Parenter Enteral Nutr 2016;40:159e211. http://
dx.doi.org/10.1177/0148607115621863.
[50] Dhaliwal R, Cahill N, Lemieux M, Heyland D. The Canadian critical care
nutrition guidelines in 2013: an update on current recommendations and
implementation strategies. Nutr Clin Pract 2014;29:29e43. http://dx.doi.org/
10.1177/0884533613510948.
[51] Bernard GR. Acute respiratory distress syndrome. Am J Respir Crit Care Med
2005;172:798e806. http://dx.doi.org/10.1164/rccm.200504-663OE.
[52] ARDS Definition Taskforce, Ranieri V, Rubenfeld G, Thompson B, Ferguson N,
Caldwell E, et al. Acute respiratory distress syndrome e the Berlin definition.
JAMA 2012;307:1e8. http://dx.doi.org/10.1001/jama.2012.5669.
[53] Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. Report of
the American-European consensus conference on ARDS: definitions, mech-
anisms, relevant outcomes and clinical trial coordination. Am J Respir Crit
Care Med 1994;149:818e24. http://dx.doi.org/10.1007/BF01704707.
[54] Mayer K, Kiessling A, Ott J, Schaefer MB, Hecker M, Henneke I, et al. Acute
lung injury is reduced in fat-1 mice endogenously synthesizing n-3 fatty
acids. Am J Respir Crit Care Med 2009;179:474e83. http://dx.doi.org/
10.1164/rccm.200807-1064OC.
[55] Murray M, Kumar M, Gregory T, Banks P, Tazelaar H, DeMichele S. Select
dietary fatty acids attenuate cardiopulmonary dysfunction during acute lung
injury in pigs. Am J Physiol 1995;269:H2090e9.
[56] Gadek J, DeMichele S, Karlstad M, Pacht E, Donahoe M, Albertson T, et al.
Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid,
and antioxidants in patients with acute respiratory distress syndrome.
Enteral Nutrition in ARDS Study Group. Crit Care Med 1999;27:1409e20.
[57] Singer P, Theilla M, Fisher H, Gibstein L, Grozovski E, Cohen J. Benefit of an
enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid
in ventilated patients with acute lung injury. Crit Care Med 2006;34:1033e8.
http://dx.doi.org/10.1097/01.CCM.0000206111.23629.0A.
[58] Pontes-Arruda A, Aragao AMA, Albuquerque JD. Effects of enteral feeding
with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in
mechanically ventilated patients with severe sepsis and septic shock. Critcare unit: Recommendations from the ESPEN Expert Group, Clinical
P.C. Calder et al. / Clinical Nutrition xxx (2017) 1e18 15Care Med 2006;34:2325e33. http://dx.doi.org/10.1097/01.CCM.00002340
33.65657.B6.
[59] Elamin EM, Miller AC, Ziad S. Immune enteral nutrition can improve out-
comes in medical-surgical patients with ARDS: a prospective randomized
controlled trial. J Nutr Disord Ther 2012;2:109. http://dx.doi.org/10.4172/
2161-0509.1000109.
[60] Grau-Carmona T, Moran-García V, García-de-Lorenzo A, Heras-de-la-Calle G,
Quesada-Bellver B, Lopez-Martínez J, et al. Effect of an enteral diet enriched
with eicosapentaenoic acid, gamma-linolenic acid and anti-oxidants on the
outcome of mechanically ventilated, critically ill, septic patients. Clin Nutr
2011;30:578e84. http://dx.doi.org/10.1016/j.clnu.2011.03.004.
[61] Rice TW. Enteral omega-3 fatty acid, g-linolenic acid, and antioxidant sup-
plementation in acute lung injury. JAMA 2011;306:1574. http://dx.doi.org/
10.1001/jama.2011.1435.
[62] Stapleton RD, Martin TR, Weiss NS, Crowley J, Gundel SJ, Nathens AB, et al.
A phase II randomized placebo-controlled trial of omega-3 fatty acids for the
treatment of acute lung injury. Crit Care Med 2011;39:1655e62. http://
dx.doi.org/10.1097/CCM.0b013e318218669d.A.
[63] Felbinger T, Weigand M, Mayer K. Supplementation in acute lung injury.
JAMA 2012;307:144. http://dx.doi.org/10.1001/jama.2011.1985.
[64] Zhu D, Zhang Y, Li S, Gan L, Feng H, Nie W. Enteral omega-3 fatty acid
supplementation in adult patients with acute respiratory distress syndrome:
a systematic review of randomized controlled trials with meta-analysis and
trial sequential analysis. Intensive Care Med 2014;40:504e12. http://
dx.doi.org/10.1007/s00134-014-3244-5.
[65] Glenn JOH, Wischmeyer PE. Enteral fish oil in critical illness: perspectives
and systematic review. Curr Opin Clin Nutr Metab Care 2014;17:116e23.
http://dx.doi.org/10.1097/MCO.0000000000000039.
[66] Russell J. Management of sepsis. N Engl J Med 2006;355:1699e713. http://
dx.doi.org/10.1056/NEJMra043632.
[67] Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al.
Surviving sepsis campaign: international guidelines for management of
sepsis and septic shock: 2016. Intensive Care Med 2017;43:304e77. http://
dx.doi.org/10.1007/s00134-017-4683-6.
[68] Pontes-Arruda A, Martins L, de Lima S, Isola A, Toledo D, Rezende E, et al.
Enteral nutrition with eicosapentaenoic acid, g-linolenic acid and antioxi-
dants in the early treatment of sepsis: results from a multicenter, prospec-
tive, randomized, double-blinded, controlled study: the INTERSEPT Study.
Crit Care 2011;15:R144. http://dx.doi.org/10.1186/cc10267.
[69] Braga M. Nutritional approach in malnourished surgical patients: a pro-
spective randomized study. Arch Surg 2002;137:174e80. http://dx.doi.org/
10.1001/archsurg.137.2.174.
[70] Klek S, Sierzega M, Szybinski P, Szczepanek K, Scislo L, Walewska E, et al. The
immunomodulating enteral nutrition in malnourished surgical patients e a
prospective, randomized, double-blind clinical trial. Clin Nutr 2011;30:
282e8. http://dx.doi.org/10.1016/j.clnu.2010.10.001.
[71] Kagan I, Cohen J, Stein M, Bendavid I, Pinsker D, Silva V, et al. Preemptive
enteral nutrition enriched with eicosapentaenoic acid, gamma-linolenic acid
and antioxidants in severe multiple trauma: a prospective, randomized,
double-blind study. Intensive Care Med 2015;41:460e9. http://dx.doi.org/
10.1007/s00134-015-3646-z.
[72] Silva V, Singer P. Membrane fatty acid composition of different target pop-
ulations: importance of baseline on supplementation. Clin Nutr Exp 2015;1:
1e9. http://dx.doi.org/10.1016/j.yclnex.2015.07.001.
[73] van Zanten ARH, Sztark F, Kaisers UX, Zielmann S, Felbinger TW,
Sablotzki AR, et al. High-protein enteral nutrition enriched with immune-
modulating nutrients vs standard high-protein enteral nutrition and noso-
comial infections in the ICU: a randomized clinical trial. JAMA 2014;312:
514e24. http://dx.doi.org/10.1001/jama.2014.7698.
[74] Heyland D, Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, et al.
A randomized trial of glutamine and antioxidants in critically ill patients.
N Engl J Med 2013;368:1489e97. http://dx.doi.org/10.1056/NEJMoa1212722.
[75] Smirniotis V, Kostopanagiotou G, Vassiliou J, Arkadopoulos N, Vassiliou P,
Datsis A, et al. Long chain versus medium chain lipids in patients with ARDS:
effects on pulmonary haemodynamics and gas exchange. Intensive Care Med
1998;24:1029e33. http://dx.doi.org/10.1007/s001340050711.
[76] McCray S, Parrish CR. When Chyle leaks: nutrition management options.
Pract Gastroenterol 2004;May:60e76.
[77] Furukawa K, Yamamori H, Takagi K, Hayashi N, Suzuki R, Nakajima N, et al.
Influences of soybean oil emulsion on stress response and cell-mediated
immune function in moderately or severely stressed patients. Nutrition
2002;18:235e40. http://dx.doi.org/10.1016/S0899-9007(01)00784-5.
[78] Battistella F, Widergren J, Anderson J, Siepler J, Weber J, MacColl K.
A prospective, randomized trial of intravenous fat emulsion administration
in trauma victims requiring total parenteral nutrition. J Trauma 1997;43:
52e8.
[79] Adolph M, Heller A, Koch T, Koletzko B, Kreymann K, Krohn K, et al. Lip-
idemulsionen. Aktuel Ernaehr Med 2007;32:S22e9. http://dx.doi.org/
10.1055/s-2006-951866.
[80] Adolph M, Heller AR, Koch T, Koletzko B, Kreymann KG, Krohn K, et al.
Working group for developing the guidelines for parenteral nutrition of The
German Association for Nutritional Medicine. Ger Med Sci 2009;7:1e13.
http://dx.doi.org/10.3205/000081.
[81] Masini J, Fichelle A, Pescio M, Bdrdziat G, Desmonts J, Lienhart A. Tolerance
clinique et biologique et effets sur les parametres lipidiques de ClinOleic ®Please cite this article in press as: Calder PC, et al., Lipids in the intensive
Nutrition (2017), http://dx.doi.org/10.1016/j.clnu.2017.08.032compare a l'Intralipide ® chez des patients de reanimation chirurgicale. Nutr
Clin Metab 1996;10:21e4.
[82] Puiggros C, Sanchez J, Chacon P, Sabín P, Rosello J, Bou R, et al. Evolution of
lipid profile, liver function, and pattern of plasma fatty acids according to the
type of lipid emulsion administered in parenteral nutrition in the early
postoperative period after digestive surgery. J Parenter Enteral Nutr
2009;33:501e12. http://dx.doi.org/10.1038/sj.ejcn.1601961.
[83] Demirer S, Sapmaz A, Karaca AS, Kepenekci I, Aydintug S, Balci D, et al. Effects
of postoperative parenteral nutrition with different lipid emulsions in pa-
tients undergoing major abdominal surgery. Ann Surg Treat Res 2016;91:
309e15. http://dx.doi.org/10.4174/astr.2016.91.6.309.
[84] Umpierrez GE, Spiegelman R, Zhao V, Dawn D, Pinzon I, Griffith DP, et al.
A double-blind, randomized clinical trial comparing soybean oil-based
versus olive oil-based lipid emulsions in adult medicalesurgical intensive
care unit patients requiring parenteral nutrition. Crit Care Med 2012;40:
1792e8. http://dx.doi.org/10.1097/CCM.0b013e3182474bf9.A.
[85] Mateu-de Antonio J, Grau S, Luque S, Marín-Casino M, Albert I, Ribes E.
Comparative effects of olive oil-based and soyabean oil-based emulsions on
infection rate and leucocyte count in critically ill patients receiving paren-
teral nutrition. Br J Nutr 2008;99:846e54. http://dx.doi.org/10.1017/
S0007114507837433.
[86] Grau T, Ruiz de Adana J, Zubillaga S, Fuerte S, Giron C. Randomized study of
two different fat emulsions in total parenteral nutrition of malnourished
surgical patients; effect of infectious morbidity and mortality. Nutr Hosp
2003;18:159e66.
[87] Marsili I, Iovinelli G, Varrassi G. Parenteral nutrition in COPD patients: long-
vs medium-chain triglycerides (MCT). Clin Nutr 1992;11:45.
[88] Gopinath R, Yelliboina S, Singh M, Prasad VBN. Impact of supplementing
preoperative intravenous omega 3 fatty acids in fish oil on immunomodu-
lation in elderly patients undergoing hip surgery. Indian J Surg 2012;75:1e7.
http://dx.doi.org/10.1007/s12262-012-0543-3.
[89] Berger M, Delodder F, Liaudet L, Tozzi P, Schlaepfer J, Chiolero R, et al. Three
short perioperative infusions of n23 PUFAs reduce systemic inflammation
induced by cardiopulmonary bypass surgery: a randomized controlled trial.
Am J Clin Nutr 2013;97:246e54. http://dx.doi.org/10.3945/ajcn.112.046573.1.
[90] Weiss G, Meyer F, Matthies B, Pross M, Koenig W, Lippert H. Immunomo-
dulation by perioperative administration of n-3 fatty acids. Br J Nutr
2002;87:S89e94. http://dx.doi.org/10.1079/BJN2001461.
[91] Jiang ZM, Wilmore DW, Wang XR, Wei JM, Zhang ZT, Gu ZY, et al. Ran-
domized clinical trial of intravenous soybean oil alone versus soybean oil
plus fish oil emulsion after gastrointestinal cancer surgery. Br J Surg 2010;97:
804e9. http://dx.doi.org/10.1002/bjs.6999.
[92] De Miranda Torrinhas RSM, Santana R, Garcia T, Cury-Boaventura MF,
Sales MM, Curi R, et al. Parenteral fish oil as a pharmacological agent to
modulate post-operative immune response: a randomized, double-blind,
and controlled clinical trial in patients with gastrointestinal cancer. Clin
Nutr 2013;32:503e10. http://dx.doi.org/10.1016/j.clnu.2012.12.008.
[93] Zhu M, Tang D, Hou J, Wei J, Hua B, Sun J, et al. Impact of fish oil enriched
total parenteral nutrition on elderly patients after colorectal cancer surgery.
Chin Med J 2012;125:178e81.
[94] Kłek S, Kulig J, Szczepanik AM, Jedrys J, Kołodziejczyk P. The clinical value of
parenteral immunonutrition in surgical patients. Acta Chir Belg 2005;105:
175e9.
[95] Badía-Tahull MB, Llop-Talaveron JM, Leiva-Badosa E, Biondo S, Farran-
Teixido L, Ramon-Torrell JM, et al. A randomised study on the clinical progress
of high-risk elective major gastrointestinal surgery patients treated with olive
oil-based parenteral nutrition with or without a fish oil supplement. Br J Nutr
2010;104:737e41. http://dx.doi.org/10.1017/S0007114510001066.
[96] Wichmann MW, Thul P, Czarnetzki H-D, Morlion BJ, Kemen M, Jauch K-W.
Evaluation of clinical safety and beneficial effects of a fish oil containing lipid
emulsion (Lipoplus, MLF541): data from a prospective, randomized, multi-
center trial. Crit Care Med 2007;35:700e6. http://dx.doi.org/10.1097/
01.CCM.0000257465.60287.AC.
[97] Grimm H, Mertes N, Goeters C, Schlotzer E, Mayer K, Grimminger F, et al.
Improved fatty acid and leukotriene pattern with a novel lipid emulsion in
surgical patients. Eur J Nutr 2006;45:55e60. http://dx.doi.org/10.1007/
s00394-005-0573-8.
[98] Zhu XH, Wu YF, Qiu YD, Jiang CP, Ding YT. Liver-protecting effects of omega-
3 fish oil lipid emulsion in liver transplantation. World J Gastroenterol
2012;18:6141e7. http://dx.doi.org/10.3748/wjg.v18.i42.6141.
[99] Heidt MC, Vician M, Stracke SK, Stadlbauer T, Grebe MT, Boening A, et al.
Beneficial effects of intravenously administered N-3 fatty acids for the pre-
vention of atrial fibrillation after coronary artery bypass surgery: a pro-
spective randomized study. Thorac Cardiovasc Surg 2009;57:276e80. http://
dx.doi.org/10.1055/s-0029-1185301.
[100] Tsekos E, Reuter C, Stehle P, Boeden G. Perioperative administration of
parenteral fish oil supplements in a routine clinical setting improves patient
outcome after major abdominal surgery. Clin Nutr 2004;23:325e30. http://
dx.doi.org/10.1016/j.clnu.2003.07.008.
[101] Pradelli L, Mayer K, Muscaritoli M, Heller AR. n-3 fatty acid-enriched
parenteral nutrition regimens in elective surgical and ICU patients: a
meta-analysis. Crit Care 2012;16:R184. http://dx.doi.org/10.1186/cc11668.
[102] Chen B, Zhou Y, Yang P, Wan H, Wu X. Safety and efficacy of fish oil-enriched
parenteral nutrition regimen on postoperative patients undergoing major
abdominal surgery: a meta-analysis of randomized controlled trials.care unit: Recommendations from the ESPEN Expert Group, Clinical
P.C. Calder et al. / Clinical Nutrition xxx (2017) 1e1816J Parenter Enteral Nutr 2010;34:387e94. http://dx.doi.org/10.1038/
sj.ejcn.1602230.
[103] Manzanares W, Langlois PL, Dhaliwal R, Lemieux M, Heyland DK. Intrave-
nous fish oil lipid emulsions in critically ill patients: an updated systematic
review and meta-analysis. Crit Care 2015;19:1e15. http://dx.doi.org/
10.1186/s13054-015-0888-7.
[104] Wang J, Yu JC, Kang WM, Ma ZQ. Superiority of a fish oil-enriched emulsion
to medium-chain triacylglycerols/long-chain triacylglycerols in gastrointes-
tinal surgery patients: a randomized clinical trial. Nutrition 2012;28:623e9.
http://dx.doi.org/10.1016/j.nut.2011.08.004.
[105] Han Y-Y, Lai S-L, Ko W-J, Chou C-H, Lai H-S. Effects of fish oil on inflam-
matory modulation in surgical intensive care unit patients. Nutr Clin Pract
2012;27:91e8. http://dx.doi.org/10.1177/0884533611429796.
[106] Heller AR, R€ossel T, Gottschlich B, Tiebel O, Menschikowski M, Litz RJ, et al.
Omega-3 fatty acids improve liver and pancreas function in postoperative
cancer patients. Int J Cancer 2004;111:611e6. http://dx.doi.org/10.1002/
ijc.20291.
[107] Piper S, Schade I, Beschmann R, Maleck W, Boldt J, R€ohm K. Hepatocellular
integrity after parenteral nutrition: comparison of a fish-oil-containing lipid
emulsion with an olive-soybean oil-based lipid emulsion. Eur J Anaesthesiol
2009;26:1076e82.
[108] Ma CJ, Sun LC, Chen FM, Lu CY, Shih YL, Tsai HL, et al. A double-blind ran-
domized study comparing the efficacy and safety of a composite vs a con-
ventional intravenous fat emulsion in postsurgical gastrointestinal tumor
patients. Nutr Clin Pract 2012;27:410e5. http://dx.doi.org/10.1177/
0884533611436115.
[109] Metry AA, Abdelaal W, Ragaei M, Refaat M, Nakhla G. SMOFlipid versus
intralipid in postoperative ICU patients. Enliven J Anesthesiol Crit Care Med
2014;1:15.
[110] Wu M-H, Wang M-Y, Yang C-Y, Kuo M-L, Lin M-T. Randomized clinical trial
of new intravenous lipid (SMOFlipid 20%) versus medium-chain tri-
glycerides/long-chain triglycerides in adult patients undergoing gastroin-
testinal surgery. J Parenter Enteral Nutr 2014;38:800e8. http://dx.doi.org/
10.1177/0148607113512869.
[111] Tian H, Yao X, Zeng R, Sun R, Tian H, Shi C, et al. Safety and efficacy of a new
parenteral lipid emulsion (SMOF) for surgical patients: a systematic review
and meta-analysis of randomized controlled trials. Nutr Rev 2013;71:
815e21. http://dx.doi.org/10.1111/nure.12053.
[112] Von Schacky C, Fischer S, Weber PC. Long-term effects of dietary marine
omega-3 fatty-acids upon plasma and cellular lipids, platelet-function, and
eicosanoid formation in humans. J Clin Investig 1985;76:1626e31. http://
dx.doi.org/10.1172/Jci112147.
[113] Veljovic M, Mihajlovic I, Subota V, Antunovic M, Jevdjic J, Udovicic I, et al.
Effect of pretreatment with omega-3 polyunsaturated fatty acids (PUFAs) on
hematological parameters and platelets aggregation in patients during
elective coronary artery bypass grafting. Vojnosanit Pregl 2013;70:396e402.
http://dx.doi.org/10.2298/VSP1304396V.
[114] Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S, et al. ESPEN
guideline: clinical nutrition in surgery. Clin Nutr 2017. http://dx.doi.org/
10.1016/j.clnu.2017.02.013.
[115] Edmunds C, Brody R, Parrott J, Stankorb S, Heyland D. The effects of different
IV fat emulsions on clinical outcomes in critically ill patients. Crit Care Med
2014;42:1168e77. http://dx.doi.org/10.1097/CCM.0000000000000146.
[116] Wang X, Li W, Li N, Li J. u-3 Fatty acidsesupplemented parenteral nutrition
decreases hyperinflammatory response and attenuates systemic disease
sequelae in severe acute pancreatitis: a randomized and controlled study.
J Parenter Enteral Nutr 2008;32:236e41. http://dx.doi.org/10.1177/
0148607108316189.
[117] Mayer K, Fegbeutel C, Hattar K, Sibelius U, Kr€amer HJ, Heuer KU, et al. u-3 vs.
u-6 lipid emulsions exert differential influence on neutrophils in septic
shock patients: impact on plasma fatty acids and lipid mediator generation.
Intensive Care Med 2003;29:1472e81. http://dx.doi.org/10.1007/s00134-
003-1900-2.
[118] Hall TC, Bilku DK, Al-Leswas D, Neal CP, Horst C, Cooke J, et al. A randomized
controlled trial investigating the effects of parenteral fish oil on survival
outcomes in critically ill patients with sepsis: a pilot study. J Parenter Enteral
Nutr 2015;39:301e12. http://dx.doi.org/10.1177/0148607113518945.
[119] Barbosa VM, Miles EA, Calhau C, Lafuente E, Calder PC. Effects of a fish oil
containing lipid emulsion on plasma phospholipid fatty acids, inflammatory
markers, and clinical outcomes in septic patients: a randomized, controlled
clinical trial. Crit Care 2010;14:R5. http://dx.doi.org/10.1186/cc8844.
[120] Burkhart CS, Dell-Kuster S, Siegemund M, Pargger H, Marsch S, Strebel SP,
et al. Effect of n-3 fatty acids on markers of brain injury and incidence of
sepsis-associated delirium in septic patients. Acta Anaesthesiol Scand
2014;58:689e700. http://dx.doi.org/10.1111/aas.12313.
[121] Khor B-S, Liaw S-J, Shih H-C, Wang L-S. Randomized, double blind, placebo-
controlled trial of fish-oil-based lipid emulsion infusion for treatment of
critically ill patients with severe sepsis. Asian J Surg 2011;34:1e10. http://
dx.doi.org/10.1016/S1015-9584(11)60011-0.
[122] Mayer K, Gokorsch S, Fegbeutel C, Hattar K, Rosseau S, Walmrath D, et al.
Parenteral nutrition with fish oil modulates cytokine response in patients
with sepsis. Am J Respir Crit Care Med 2003;167:1321e8. http://dx.doi.org/
10.1164/rccm.200207-674OC.
[123] Grau-Carmona T, Bonet-Saris A, García-de-Lorenzo A, Sanchez-Alvarez C,
Rodríguez-Pozo A, Acosta-Escribano J, et al. Influence of n-3 polyunsaturatedPlease cite this article in press as: Calder PC, et al., Lipids in the intensive
Nutrition (2017), http://dx.doi.org/10.1016/j.clnu.2017.08.032fatty acids enriched lipid emulsions on nosocomial infections and clinical
outcomes in critically ill patients: ICU lipids study. Crit Care Med 2015;43:
1e9. http://dx.doi.org/10.1097/CCM.0000000000000612.
[124] Chen W, Jiang H, Zhou Z, Tao Y, Cai B, Liu J, et al. Is omega-3 fatty acids
enriched nutrition support safe for critical ill patients? A systematic review
and meta-analysis. Nutrients 2014;6:2148e64. http://dx.doi.org/10.3390/
nu6062148.
[125] Palmer AJ, Ho CKM, Ajibola O, Avenell A. The role of u-3 fatty acid supple-
mented parenteral nutrition in critical illness in adults. Crit Care Med
2013;41:307e16. http://dx.doi.org/10.1097/CCM.0b013e3182657578.
[126] Friesecke S, Lotze C, K€ohler J, Heinrich A, Felix SB, Abel P. Fish oil supple-
mentation in the parenteral nutrition of critically ill medical patients: a
randomised controlled trial. Intensive Care Med 2008;34:1411e20. http://
dx.doi.org/10.1007/s00134-008-1072-1.
[127] Heller AR, R€ossler S, Litz RJ, Stehr SN, Heller SC, Koch R, et al. Omega-3 fatty
acids improve the diagnosis-related clinical outcome. Crit Care Med
2006;34:972e9. http://dx.doi.org/10.1097/01.CCM.0000206309.83570.45.
[128] Koletzko B, Goulet O, Hunt J, Krohn K, Shamir R. Guidelines on paediatric
parenteral nutrition of the European Society of Paediatric Gastroenterology,
Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical
Nutrition andMetabolism (ESPEN). J Pediatr Gastroenterol Nutr 2005;41(Suppl
2):S1e87. http://dx.doi.org/10.1097/01.mpg.0000181841.07090.f4.
[129] Lapillonne A, Kermorvant-duchemin E. A systematic review of practice
surveys on parenteral nutrition for preterm infants. J Nutr 2013:2061Se5S.
http://dx.doi.org/10.3945/jn.113.176982.2061S.
[130] Uthaya S, Modi N. Practical preterm parenteral nutrition: systematic litera-
ture review and recommendations for practice. Early Hum Dev 2014;90:
747e53. http://dx.doi.org/10.1016/j.earlhumdev.2014.09.002.
[131] Calder PC. Docosahexaenoic acid. Ann Nutr Metab 2016;69:8e21. http://
dx.doi.org/10.1159/000448262.
[132] Vlaardingerbroek H, Veldhorst MAB, Spronk S, Van Den Akker CHP, Van
Goudoever JB. Parenteral lipid administration to very-low-birth-weight in-
fants e early introduction of lipids and use of new lipid emulsions: a sys-
tematic review and meta-analysis. Am J Clin Nutr 2012;96:255e68. http://
dx.doi.org/10.3945/ajcn.112.040717.
[133] Vlaardingerbroek H, Vermeulen MJ, Rook D, Van Den Akker CHP, Dorst K,
Wattimena JL, et al. Safety and efficacy of early parenteral lipid and high-
dose amino acid administration to very low birth weight infants. J Pediatr
2013;163:638e44. http://dx.doi.org/10.1016/j.jpeds.2013.03.059. e5.
[134] Roelants JA, Vlaardingerbroek H, van den Akker CHP, de Jonge RCJ, van
Goudoever JB, Vermeulen MJ. Two-year follow-up of a randomized controlled
nutrition intervention trial in very low-birth-weight infants. J Parenter Enteral
Nutr 2016. http://dx.doi.org/10.1177/0148607116678196 (in press).
[135] A.S.P.E.N: Board of Directors. Guidelines for the use of parenteral and enteral
nutrition in adult and pediatric patients. J Parenter Enteral Nutr 2002;26:
1SAe138SA.
[136] Wales PW, De Silva N, Kim J, Lecce L, To T, Moore A. Neonatal short bowel syn-
drome: population-based estimates of incidence and mortality rates. J Pediatr
Surg 2004;39:690e5. http://dx.doi.org/10.1016/j.jpedsurg.2004.01.036.
[137] Diamond IR, Sterescu A, Pencharz PB, Kim JH, Wales PW. Changing the
paradigm: Omegaven for the treatment of liver failure in pediatric short
bowel syndrome. J Pediatr Gastroenterol Nutr 2009;48:209e15. http://
dx.doi.org/10.1097/MPG.0b013e318182c8f6.
[138] Wales PW, De Silva N, Kim JH, Lecce L, Sandhu A, Moore AM. Neonatal short
bowel syndrome: a cohort study. J Pediatr Surg 2005;40:755e62. http://
dx.doi.org/10.1016/j.jpedsurg.2005.01.037.
[139] Squires RH, Duggan C, Teitelbaum DH, Wales PW, Balint J, Venick R, et al.
Natural history of pediatric intestinal failure: initial report from the pediatric
intestinal failure consortium. J Pediatr 2012;161:723e8. http://dx.doi.org/
10.1016/j.jpeds.2012.03.062. e2.
[140] Beath SV, Davies P, Papadopoulou A, Khan AR, Buick RG, Corkery JJ, et al.
Parenteral nutrition-related cholestasis in postsurgical neonates: multivar-
iate analysis of risk factors. J Pediatr Surg 1996;31:604e6. http://dx.doi.org/
10.1016/S0022-3468(96)90507-2.
[141] Nandivada P, Cowan E, Carlson SJ, Chang M, Gura KM, Puder M. Mechanisms
for the effects of fish oil lipid emulsions in the management of parenteral
nutrition-associated liver disease. Prostagl Leukot Essent Fat Acids 2013;89:
153e8. http://dx.doi.org/10.1016/j.plefa.2013.02.008.
[142] Salvador A, Janeczko M, Porat R, Sekhon R, Moewes A, Schutzman D. Ran-
domized controlled trial of early parenteral nutrition cycling to prevent
cholestasis in very low birth weight infants. J Pediatr 2012;161:229e33.
http://dx.doi.org/10.1016/j.jpeds.2012.02.003.
[143] Jensen AR, Goldin AB, Koopmeiners JS, Stevens J, Waldhausen JHT, Kim SS.
The association of cyclic parenteral nutrition and decreased incidence of
cholestatic liver disease in patients with gastroschisis. J Pediatr Surg
2009;44:183e9. http://dx.doi.org/10.1016/j.jpedsurg.2008.10.033.
[144] Rangel SJ, Calkins CM, Cowles RA, Barnhart DC, Huang EY, Abdullah F, et al.
Parenteral nutrition-associated cholestasis: an American pediatric surgical as-
sociation outcomes and clinical trials committee systematic review. J Pediatr
Surg 2012;47:225e40. http://dx.doi.org/10.1016/j.jpedsurg.2011.10.007.
[145] Kubota A, Okada A, Imura K, Kawahara H, Nezu R, Kamata S, et al. The effect
of metronidazole on TPN-associated liver dysfunction in neonates. J Pediatr
Surg 1990;25:618e21.
[146] SrivastavaB,GimsonA.Hepatic changes in systemic infection. Best Pract Res Clin
Gastroenterol 2013;27:485e95. http://dx.doi.org/10.1016/j.bpg.2013.06.011.care unit: Recommendations from the ESPEN Expert Group, Clinical
P.C. Calder et al. / Clinical Nutrition xxx (2017) 1e18 17[147] Cober MP, Killu G, Brattain A, Welch KB, Kunisaki SM, Teitelbaum DH.
Intravenous fat emulsions reduction for patients with parenteral nutrition-
associated liver disease. J Pediatr 2012;160:421e7. http://dx.doi.org/
10.1016/j.jpeds.2011.08.047.
[148] Rollins MD, Ward RM, JacksonWD, Mulroy CW, Spencer CP, Ying J, et al. Effect
of decreased parenteral soybean lipid emulsion on hepatic function in infants
at risk for parenteral nutrition-associated liver disease: a pilot study. J Pediatr
Surg 2013;48:1348e56. http://dx.doi.org/10.1016/j.jpedsurg.2013.03.040.
[149] Sanchez SE, Braun LP, Mercer LD, Sherrill M, Stevens J, Javid PJ. The effect of
lipid restriction on the prevention of parenteral nutrition-associated chole-
stasis in surgical infants. J Pediatr Surg 2013;48:573e8. http://dx.doi.org/
10.1016/j.jpedsurg.2012.08.016.
[150] Muhammed R, Bremner R, Protheroe S, Johnson T, Holden C, Murphy MS.
Resolution of parenteral nutrition-associated jaundice on changing from a
soybean oil emulsion to a complex mixed-lipid emulsion. J Pediatr Gastro-
enterol Nutr 2012;54:797e802. http://dx.doi.org/10.1097/MPG.0b
013e3182447daf.
[151] Attard M, Patel N, Simpson J. Change from intralipid to SMOF lipid is asso-
ciated with improved liver function in infants with PN associated liver dis-
ease. Arch Dis Child 2012;97:A54e5.
[152] Orso G, Mandato C, Veropalumbo C, Cecchi N, Garzi A, Vajro P. Pediatric
parenteral nutrition-associated liver disease and cholestasis: novel advances
in pathomechanisms-based prevention and treatment. Dig Liver Dis
2016;48:215e22. http://dx.doi.org/10.1016/j.dld.2015.11.003.
[153] Chan S, McCowen KC, Bistrian BR, Thibault A, Keane-Ellison M, Forse RA,
et al. Incidence, prognosis, and etiology of end-stage liver disease in patients
receiving home total parenteral nutrition. Surgery 1999;126:28e34. http://
dx.doi.org/10.1067/msy.1999.98925.
[154] Beath SV, Kelly DA. Total parenteral nutrition-induced cholestasis: preven-
tion and management. Clin Liver Dis 2016;20:159e76. http://dx.doi.org/
10.1016/j.cld.2015.08.009.
[155] Carter BA, Taylor OA, Prendergast DR, Zimmerman TL, Von Furstenberg R,
Moore DD, et al. Stigmasterol, a soy lipid-derived phytosterol, is an antag-
onist of the bile acid nuclear receptor FXR. Pediatr Res 2007;62:301e6.
http://dx.doi.org/10.1203/PDR.0b013e3181256492.
[156] Nandivada P, Fell GL, Gura KM, Puder M. Lipid emulsions in the treatment
and prevention of parenteral nutrition e associated liver disease in infants
and children. Am J Clin Nutr 2016;103:629e35. http://dx.doi.org/10.3945/
ajcn.114.103986.1.
[157] deMeijer V, Gura K,Meisel J, Le H, PuderM. Parenteral fish oilmonotherapy in
the management of patients with parenteral nutritioneassociated liver dis-
ease. Arch Surg 2010;145:547. http://dx.doi.org/10.1001/archsurg.2010.80.
[158] Vlaardingerbroek H, Vermeulen M, Carnielli V, Vaz F, van den Akker C, van
Goudoever J. Growth and fatty acid profiles of VLBW infants receiving a
multicomponent lipid emulsion from birth. J Pediatr Gastroenterol Nutr
2014;58:417e27. http://dx.doi.org/10.1097/MPG.0000000000000280.
[159] Beken S, Dilli D, Fettah ND, Kabataş EU, Zenciroǧlu A, Okumuş N. The in-
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